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Background 
Gout is one of the most common rheumatological conditions and appears to have a 
higher prevalence in certain populations Risk factors for gout and its precursor, 
hyperuricemia, are also significant risk factors for preeclampsia, a major pregnancy-
related morbidity. We hypothesized that uric acid (UA) allele frequencies are associated 
with certain populations and the development of preeclampsia. This project aimed to 
assess UA risk allele frequencies across a diverse cohort of pregnant individuals and to 
determine if UA risk allele are associated with risk factors for preeclampsia. 
Methods 
A retrospective cross-sectional study was conducted on pregnant women from different 
ethnicities who 100% reported their ethnicities from the Asian Pacific Islander 
population. Numerous UA genes and clinical conditions were addressed, and all study 
details were reviewed and exempted by the University of Hawaii human Studies 
Program (Protocol Number: 2018-00225). The biospecimens repository at the 
University of Hawaii provided DNA samples, medical information, and demographic 
data on study participants. These samples were collected after receiving written consent. 
DNA was extracted from cord blood samples, and genotyping was performed at the 
Cancer Center's Genomics and Bioinformatics Shared Resource (Honolulu, HI).   
x 
Our primary outcome was to assess the frequencies of the eight UA risk alleles provided 
by the biospecimens repository across the Asian, Native Hawaiian, and Pacific Islander 
populations compared to European (EUR) ancestry. All UA risk alleles and genotypes 
for EUR were estimated from the Ensembl genome browser. Our secondary outcome 
was to assess the role of both UA risk alleles and other factors involving age/BMI 
contributing to CMDs in Filipino and Samoan subgroups. We estimated the proportion 
of UA genotype in the presence and absence of the CMDs. Moreover, we tested for 
association between CMDs and both age and BMI. Finally, we compared mean BMI 
among different UA genotypes across the Filipino and Samoan populations.  
Results 
In this study, 1059 pregnant women aged 18 or older self-reported their race and 
ethnicity, including Asian, Native Hawaiian, and Pacific Islander populations. The UA 
risk alleles frequencies amongst our participants differed from EUR. Compared to EUR, 
8/8 UA risk alleles were found in Japanese, 6/8 in Korean, 6/8 in Filipino, 8/8 in 
Samoan, 6/8 in Hawaiian, and 6/8 in Marshallese. The HU/gout risk alleles indices were 
8, 5, 6, 5, 4, and 4 in Japanese, Koreans, Filipinos, Samoans, Marshallese, and 
Hawaiians, respectively. Out of the eight SNPs, the risk alleles associated with HU/gout 
in Japanese and Filipino were 100%, followed by 83.5% in Korean. In addition, we 
found alleles at the ABCG2 gene to be associated with increased risk of diabetes 
mellitus in the Filipino population under both additive and recessive genetic models, p 
<0.05. Under the recessive genetic model, we found that SLC22A11 alleles were 
trending towards a significant association with the development of chronic hypertension 
(p=0.085) and gestational diabetes mellitus (p=0.063) in the Samoan subgroup. 
Using logistic regression analysis. we found both age and BMI were associated with 
increased risk of chronic hypertension across the Filipino subgroup (OR= 1.06, 95% 
xi 
CI= 0.99- 1.13, p= 0.06 (BMI), and (OR= 1.11, 95% CI= 1.02- 1.22, p=0.013 (Age)). 
Moreover, age factor was associated with gestational diabetes mellitus development 
across the Samoan population (OR=1.15, 95% CI 1.06- 1.25, p=0.0006). Finally, 
ANOVA test showed lower mean BMI in both Filipino and Samoan subjects carrying 
risk genotypes compared to wild-type genotype.  
Conclusion 
Our study found that Asian pregnant women had a higher prevalence of UA risk alleles 
compared to the EUR population. The Asian population is at high risk of 
cardiometabolic disorder prevalence, and we found UA risk alleles may be associated 
with developing CMDs across the Asian population. This is the first study of its type to 
look at the genetics of uric acid in ethnicities who are underrepresented in studies. This 
research is considered the first report to estimate the UA risk allele and nongenetic 
factors (age and BMI) and their role in CMDs across different ethnicities. We 
recommend that further studies be conducted on large sample sizes and in different 
locations to validate our findings. 
Keywords: Gout, Hyperuricemia, Uric acid, Cardiometabolic diseases, Single nucleotide 
polymorphisms, European ancestry, Asian, Native Hawaiian, Pacific Islander, 
Pregnancy
 1 
Chapter 1:  Introduction of hyperuricemia and gout disease 
 
 2 
Hyperuricemia and Gout definitions 
        Gout is an inflammatory arthritic condition characterized by precipitation of 
monosodium urate (MSU) crystals in or around joints due to chronic elevation of serum urate 
(SU), exceeding saturation point.1 Several factors could lead to gout, including both genetic 
and non-genetic risk factors.2 Hyperuricemia (HU) resulted due to excessive production or 
under excretion of uric acid.3 Genetic, comorbidities and environmental factors are major 
contributors to HU 4, which is defined as serum uric acid levels of more than 7 mg/dl in men 
and 6 mg/dl in women (Table 1.1).1 
Epidemiology of hyperuricemia and gout 
        Gout is one of the most frequent inflammatory arthritis. It is critical to evaluate its 
prevalence patterns in order to prepare for adequate health care resources. Unfortunately, 
epidemiologic data is limited, variable, and without a standard approach to diagnosis. A 
systematic review that aimed to collect data from different regions around the world to 
estimate the differentiation in gout prevalence and incidence reported that the data indicating 
gout distribution globally is unclear due to the lack of standardized methods used to diagnose 
gout in developed and developing countries.5  
        The prevalence and incidence of gout and hyperuricemia are more common in 
developed rather than developing countries. The prevalence of gout has remained high since 
ancient times, but it has more than doubled over the last 20 years.6,7  Globally, reports 
indicate that the prevalence of gout ranges from 0.1% to about 10%, with an incidence rate 
ranging from 0.3 to 6 cases per 1,000 person-years.5  
On the one hand, the prevalence of gout in developed countries estimated >1% in countries 
like North America and Europe. Furthermore, Europe, Greece has the highest gout 
prevalence of about 4.75% among the adult community8, whereas in Portugal (about 0.3%) 
among adults.9 A previously published survey reported that the Japanese and South Korean 
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populations had the lowest incidence of gout, which is 0.51% (2003) and 0.4% (2008), 
respectively, using the health insurance database. Moreover, Taiwan, Hong Kong, and 
Singapore reported a much higher prevalence of gout. The Hong Kong population aged 45–
59 was shown to have a 5.1% prevalence, while those older than 60 years had a gout 
prevalence of 6.1%. In Singapore and Taiwan, the prevalence was reported as 4.1% and 
4.92%, respectively, in 2004.5 Other study has reported that gout incidence in South Korea 
increased by 25% between 2009 and 2015.10   
        In the USA, the National Health and Nutrition Examination Survey (NHANES) from 
2015 to 2016, combined with data from 5467 subjects consisting of both men and women in 
the United States (US), has reported that the gout prevalence is approximately 3.9% among 
the US adult population, affecting roughly 9.2 million persons, with men having a higher 
gout prevalence rate than women [5.2% (5.9 million) versus 2.7% (3.3 million)].11 In 
addition, the means that serum urate levels were 6.0 mg/dl in men and 4.8 mg/dl in women. 
Hence, the prevalence of hyperuricemia was 20.2% and 20.0% in men and women, 
respectively (Table 1.2).11 
        On the other hand, a community-oriented program for the control of rheumatic diseases 
(COPCORD) survey was conducted among 15 developing countries to estimate the 
prevalence of gout. The prevalence of gout in Central and South America was low, with a 
rate of 0.3% to 0.4% in Mexico, Cuba, and Venezuela 12,13, compared with Asian countries 
such as Indonesia, which had a gout prevalence of 1.7%, and Kuwait, which had a gout 
prevalence of 0.8%, while other Asian countries reported gout prevalence of less than 0.5%.5 
         A limited diagnosis tool or absence of gout flare symptoms impact the gout disease 
reports. For instance, asymptomatic hyperuricemia is common in some countries but goes 
undiagnosed. Aside from this, a study conducted in Saudi Arabia which interviewed 487 
Saudi participants in 14 primary care clinics in Riyadh over seven months from September 
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1998 to March 1999 indicated that up to 8.2% of people (males and females) had high SU, 
but none of them had symptoms of gout.14 Thus, it is clear that the prevalence of gout is 
highest in developed countries, whereas data is lacking for some parts of the developing 
world, particularly Africa and South America.15  
        In summary, gout prevalence varies globally, with the highest prevalence reported in 
Oceanic countries, particularly in indigenous and South Pacific Island populations, and the 
lowest prevalence in the developing world. In addition to the previously reported increasing 
prevalence of gout in Europe and the USA, there is evidence of increasing prevalence in 
Australia (self-reported), Canada, China, and South Korea.15 
 
Pathophysiology of Gout  
        Physiologically, HU occurs via increased catabolism of purine substances or under 
excretion of UA from the body. These mechanisms could result from different circumstances, 
as motioned before16 Purine production could occur through endogenous or exogenous 
pathways. Nucleic acid degradation, known as the endogenous process, HU could also occur 
by exogenous due to numerous factors, which eventually convert to uric acid.17 
Physiologically, enzymes dysfunction, mainly those responsible for the balance of 
endogenous purine production, could cause increased activity of 5’-ribosyl-1’-pyrophosphate 
(PRPP) synthetase and a decrease in hypoxanthine phosphor-ribosyltransferase enzyme 
(HPRT). Hence, these enzyme defects may result in excessive purine production.18 In 
addition, several clinical conditions, including rhabdomyolysis, hemolysis, and tumor lysis 
syndrome, are prime examples of cell turnover and significant purine sources, which 
eventually lead to increased urate production.3   
        Once purine is converted to UA and exceeds the normal range, that leads to the 
formation of monosodium urate (MSU) crystals that precipitate in the synovial fluid and soft 
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tissues, causing signs and symptoms of acute gout flares.11 MSU deposits trigger the 
inflammatory pathways through the activation of macrophages, which have a role in releasing 
inflammatory cytokines, such as interleukin (IL-1β). This chemical release leads to the onset 
of acute gout flare that is characterized by erythema, swelling, and severe pain, in addition to 
neutrophil-activated proinflammatory mediators, such as arachidonic acid, prostaglandins 
(PGE), leukotriene (LTB), and NLRR3 inflammasome. NLRR3 is an innate immune system 
component that may trigger a range of cellular damage and the release of proinflammatory 
cytokines such as IL-1B/IL-18.19  (Figure 1.1)20 
        The renal system eliminates two-thirds of uric acid generated in the body and the gut 
excretes the remaining one-third. Thus, changes in renal function may impact uric acid 
removal from the body through increased absorption or decreased excretion.3 On the other 
hand, impairment of kidney function is not always the main reason for uric acid under 
excretion. Uric acid under excretion may be due to genetic defects or variations in renal uric 
acid transporter genes, such as the ATP binding cassette subfamily G (ABCG2), glucose 
transporter 9 (SLC2A9), and others.21  
Genetics of hyperuricemia and gout 
        The interaction between genetic variants and environmental factors can explain the 
development of hyperuricemia and its progression to gout. Urate heritability has been 
estimated to be between 45% and 73%.22 One of the largest genome-wide association studies 
(GWAS) conducted in over 110,000 people of European and other ancestries discovered 28 
loci associated with urate.23 These loci are dominated by genes encoding the uric acid 
transporters in the kidney and the gastrointestinal system (SLC2A9/GLUT9, ABCG2, 
SLC22A11/OAT4, SLC22A12/URAT1, SLC17A1/NPT1, and the scaffolding protein gene 
PDZK1).22 (Figure 1.2)24  
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        Several genes were reported to influence the excretion or reabsorption of uric acid.25 For 
example, the ATP-binding cassette transporter is located in the apical membrane in the renal 
proximal tubule and is responsible for urate excretion. ABCG2 is a gene transporter for UA in 
the proximal tubular cells of the kidney and the gastrointestinal (GI) tract. The ABCG2 gene 
encodes an ATP transporter, so the presence of polymorphisms may cause clinical 
consequences, either a higher or lower risk of HU/gout. The ABCG2 gene possesses a high 
capacity and affinity for uric acid excretion and is expressed in different tissues, including the 
kidneys, intestines, and liver. Therefore, this gene’s polymorphism could lead to decreased 
urate excretion 26 and an inadequate response to medication, such as the urate-lowering 
therapy allopurinol.27  
        A meta-analysis conducted in Aotearoa, New Zealand, demonstrated that a 
particular ABCG2 gene, rs2231142 polymorphism, is associated with the adequate response 
levels of allopurinol. The missenses variant of ABCG2 141K could increase allopurinol 
concentration in the kidney tubules and decrease concentration in the tubular fluid. This can 
result in reduced or inhibited SU excretion from the kidneys, causing inadequate allopurinol 
response. 27 Another example is the SLC2A9 (GLUT9) gene, which has a high-affinity urate 
transporter. It has a role in SU re-absorption and might lead to renal hypouricemia due to loss 
of function.28’29 Meanwhile, genetic polymorphisms of some genes, such as inhibin beta C 
(INHBC), a transforming growth factor (TGF)-β gene product in the super-family of proteins, 
could lead to an increase in the risk for gout flares through numerous cellular processes.30 
        SLC17A1 and SLC17A3 transportome genes are involved in the urate transporter and 
located in the apical side of the kidneys. Other genes involved in regulating SU include the 
SLC22A11, GCKR, LRRC16A, and PDZK1 genes.31’32 The prevalence of hyperuricemia and 
gout across a given population is also associated with race and ethnicity. These differences 
may make some ethnicities more susceptible to the diseases, gout in particular, than others. 
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For example, African-American (AA) groups have more gout risk compared to their 
European counterparts (EUR).33 Asian populations, including Japanese and Han-Chinese, are 
also at high risk of gout relative to EUR ancestry.34 This research confirms that the 
prevalence of hyperuricemia and gout among people varies across different populations.  
        Moreover, several risk factors could be both genetic and non-genetic in regard to an 
individual’s susceptibility to HU/gout development as previously mentioned. Genetically 
many single nucleotide polymorphisms (SNPs) in genes involved in uric acid regulation play 
an important role in distinguishing the frequency and incidence of gout amongst ethnic 
groups. According to a study conducted in 2014 by Sakiyama et al. in which the ethnic 
differences of polymorphism of the ABCG2 gene among three populations were examined, it 
was shown that differences with respect to ABCG2 rs2231142 polymorphism, which causes 
variations in uric acid regulation and drug response, do exist among three ethnicities, namely 
Japanese, Caucasian, and African-American.35 
 
Risk factors of hyperuricemia and gout 
        Several risk factors are associated with developing HU/gout, and these factors are 
classified into modifiable and non-modifiable factors.36 Non-modifiable risk factors include 
age, sex, race, and genetic polymorphisms in the UA transportome. In contrast, lifestyle and 
some dietary habits involve alcohol consumption, purine-rich foods, fructose/sugar-
sweetened beverages, and other dietary aspects, which contribute to an increase in the risk of 
HU/gout. These factors can be avoided to reduce the risk of HU/ gout development. 
Depending on gender, men are generally at a higher risk of gout than women of all ages. The 
main reason for the difference in uric acid levels between men and women is the uricosuric 
action of the estrogen hormone, which helps enhance uric acid excretion in females. 
However, the risk of gout increases in postmenopausal women, which could be mitigated by 
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using hormone replacement therapy.37,38 The biological function of organs such as kidneys 
declines with increased age, suggesting that age could be a risk factor in the development of 
HU/gout since two-thirds of SU is eliminated by the renal system.39  
         Genetic risk factors constitute a large part of developing hyperuricemia and gout either 
through rare monogenic disorders or urate transporter polymorphisms. Lesch-Nyhan 
Syndrome is an example of a monogenic disease caused by the deficiency of HPRT, which 
may result in HU with hyperuricosuria.18 So far, genome-wide association studies (GWAS) 
have reported many UA genes related to HU/gout development. These studies were 
performed amongst different populations, and specifically targeted UA genes such as 
ABCG2, SLC2A9, and SLC22A12. The loss of function of these genes may lead to a higher or 
lower risk of gout. For example, among multiple populations, including White, African, and 
Asian groups, a significant association was found between rs2231142 SNP and increased SU 
(due to a 53% reduction in ABCG2 function), resulting in a decrease in uric acid efflux.4  
        Other types of risk factors that have been identified as having the potential to induce 
HU/gout include alcohol consumption, protein/purine-rich food, and beverages containing 
fructose/sugar, as well as other lifestyle choices. Consuming a high amount of alcohol is 
associated with an increased risk of HU/gout due to the ethanol catabolism mechanism. 
Ethanol catabolism leads to purine degradation, resulting in the formation of lactic acidosis, 
which affects renal UA excretion.40 Diets including a high amount of purine, such as seafood, 
red meat, and foods with high carbohydrate levels have also been linked with the increased 
incidences of HU/gout.41  
        Additionally, current studies have found a strong relationship between fructose intake 
and ongoing hyperuricemia and gout. In a study conducted by Martin Underwood in 2008, it 
was shown that “consuming two servings a day of any sugar-sweetened soft drink will 
increase the risk of developing gout by 85%” (relative risk 1.85, 95% confidence interval [CI] 
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1.08–3.16).42 Consumption of high-fructose corn syrup could increase the risk of gout 
through elevated uric acid production by a prompted breakdown of ATP.43  Additionally, 
obesity, in which the body mass index registers 30 kg/m2 or more, could interact with other 
factors, causing an increase in the possibility of the incidence of gout44, whereas consuming 
low-fat dairy products, coffee, and vitamin C supplements might be beneficial for minimizing 
the risk of gout.45’44 
Comorbidities diseases and gout 
        The relationship between gout and comorbidities, such as cardiovascular conditions, 
renal impairment, and metabolic syndrome, may be exacerbated by high uric acid levels.46 
Since the late 19th century, cardiovascular disease (CVD) has been recognized as one of the 
several chronic disorders that may appear as part of diseases associated with HU. However, 
this relationship is still the subject of debate, although the risk of CVD development has been 
shown to increase among patients with serum uric acid levels of more than 6 mg/dl.47,48  
Physiologically, HU could increase the production of reactive oxygen species (ROS), which 
then leads to a decrease in nitric oxide (NO) bioavailability. Decreasing the NO may lead to 
endothelial dysfunction, causing vasoconstriction and cardiac dysfunction. Likewise, 
decreasing NO activates the renin-angiotensin system (RAS), which may increase the 
possibility of cardiovascular damage.49 Moreover, gout was shown to be strongly correlated 
with a risk of chronic kidney disease (CKD) up to three-fold in older people aged 65–74 
years with a hazard ratio (HR) of 3.05 (95% CI 2.99–3.10).50 HU may contribute to 
decreasing kidney function by activation of the nucleotide-binding domain, leucine-rich 
repeat (NALP3) inflammasome, which leads to stimulation of interleukin (IL)-1β and IL-18 
and other pro-inflammatory cytokines and contributes to CKD progression.49  
        High uric acid levels contribute to hyperinsulinemia and insulin resistance (IR) via 
stimulation of mitochondrial oxidative stress, which plays an essential role in causing a 
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decrease in insulin signaling. Moreover, HU inhibits signaling enzymes, such as protein 
kinase B (AKT) and adenosine monophosphate (AMP), activated protein kinase (AMPK) 
phosphorylation that influences the glucose metabolic pathway. The inhibition 
phosphorylation of these enzymes might result in decreased hepatic glucose production, 
ultimately causing IR.52 IR can lead to other complications, such as type 2 diabetes (T2DM), 
which is recognized as one of the most common clinical syndromes due to the development 
of impaired insulin-mediated glucose transport 4 (GLUT4).53 Other metabolic syndrome 
subsets, such as dyslipidemia and hypertension, could occur, causing an increased risk of 
cardiovascular disease risks.54 (Figure 1.3)55  
        These biological observations beg the question of whether urate-lowering therapy (ULT) 
in patients that have hyperuricemia could assist in improving metabolic syndrome and 
increasing insulin sensitivity. A few studies reported that ULT could support a reduction in 
IR, hence patients who have already used benzbromarone have a significantly lower risk of 
developing diabetes than other hyperuricemia patients, as shown by data from the Taiwan 
National Health Insurance Program (HR = 0.86; 95% CI 0.79–0.94).56 A more recent analysis 
of a US cohort heavily enriched for stroke found that hyperuricemia was associated with 
stroke (HR 1.42, 95% CI 1.12-1.80), but this association seemed primarily mediated by the 
effect of treatment-resistant hypertension (full adjustment HR 1.17, 95% CI 0.87-1.56).57 
Other reported gout associations with co-morbidities, including macular degeneration58, 
erectile dysfunction59, atrial fibrillation60, and thrombo-embolism61, are an attestation to the 
complexities that rheumatologists and other providers caring for gout have to consider when 




        HU could occur as a result of a particular medication's side effects. Many 
pharmacological classes have been reported as being associated with inducing HU. For 
instance, diuretics, anti-tubercular drugs, immunosuppressant agents, nicotinic acid, low-dose 
aspirin, cytotoxic chemotherapy, non-glucose carbohydrate, lactate infusion, and testosterone 
can all promote uric acid production or inhibit uric acid excretion.63  
        Diuretics are commonly prescribed medications that improve outcomes in patients with 
cardiovascular diseases.64 Diuretic pharmacotherapy increases the risk of HU by 
approximately 6% to 21%.63 Loop and thiazide-diuretic, for example,  may induce HU due to 
the inhibition of SU excretion in the proximal renal tubule through causing alterations in such 
transporters, like organic anion transporters (OAT)1 and 3 and human sodium phosphate 
transporter (NPT)-4.63,65 Furthermore, loop diuretics such as furosemide induced a high level 
of lactic acidemia that interacts with urate elimination.66  
        Anti-tubercular drugs, such as pyrazinamide and ethambutol, have been associated with 
an increase in SU, which could lead to HU and acute gout flares. Studies have proposed a 
strong relationship between the use of pyrazinamide and developing gout. Pyrazinamide 
inhibits urate excretion up to 80% due to extensive urate retention in a therapeutic dose of 
300 mg/day.67 Ethambutol also alters SU by reducing the fractional excretion of uric acid. 
Hence, 43% to 100% of patients who receive ethambutol may develop HU.63,65 
        Calcineurin inhibitors are a group of medications that inactivate immune cells; they are 
used after an organ transplant to reduce tissue rejection.68 Certain immunosuppressant agents 
should be used after tissue transplant, including cyclosporine, tacrolimus, and mizoribine, all 
of which may increase uric acid levels.69 Cyclosporine is extensively used post-transplant of 
organs, including kidney, heart, and liver. Cyclosporine induces HU and acute gout flare due 
to an increase in urate reabsorption, mainly when administered with diuretics due to arteriolar 
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vasoconstriction that leads to a decrease in glomerular function.63 Cyclosporine has been 
found to produce a more significant effect regarding inducing HU compared to other immune 
suppression agents, such as azathioprine (84% versus 30%, respectively, p-value < 0.0001).70  
        Tacrolimus immune suppressive agent is similarly causing an increased incidence of 
HU, but a recent study demonstrated that Tacrolimus has fewer effects on SU levels than 
cyclosporine with a mean (+/- standard deviation) level of uric acid (303±75 μmol/L versus 
344 ± 62 μmol/L; P= 0.006.71 Nevertheless, some studies have concluded that there is an 
insignificant difference between either agent in inducing hyperuricemia.72  
        Mizoribine is another type of immunosuppressant agent used with transplant patients, 
mainly in the Asian population. Also, other clinical uses of mizoribine are in patients who 
suffer from lupus nephritis, rheumatoid arthritis, and nephrotic syndrome.73 Mizoribine-
induced  HU is primarily due to the inhibition of guanine nucleotides synthesis.63  
        Nicotinic acid, identified as niacin or vitamin B3, has been used since 1955 to improve 
neurological function.74 HU could result at therapeutic doses of 3 to 6 g of nicotinic acid.63 
This effect is most likely due to uric acid elimination reduction, since nicotinic acid increases 
urate reabsorption by the kidneys in addition to OAT10 transporter exchange with nicotinic 
acid, thus leading to HU. Moreover, niacin may simulate the uricase enzyme that leads to 
elevated SU levels.63,75  
        In patients with stroke, atherosclerosis, and angina, aspirin is often given as secondary 
prevention. Consequently, aspirin users have lower ischemic stroke numbers than non-aspirin 
users (OR: 0.83, 95% CI: 0.74–0.93; P = 0.45).76’77 Aspirin has a unique biphasic mechanism 
that acts on uric acid levels. A low dose of salicylate (1-2 g/day) competes for SU excretion, 
causing urate retention resulting in increased uric acid levels. Conversely, a high dose of 
salicylates (>3g/day) hinders urate reabsorption, resulting in decreased SU, an indication that 
a high dose has a uricosuric effect.78 
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        Cytotoxic chemotherapy is associated with tumor lysis syndrome (TLS). TLS results in 
the formation of excessive nucleic acids due to cell breakdown. The nucleic acids are then 
converted into hypoxanthine and xanthine to form uric acid, resulting in HU.79 As a result, 
HU is one of the most common complexities associated with cancer medications and might 
pose a serious threat to acute uric acid nephropathy. Different types of tumors such as Non-
Hodgkin’s lymphoma, solid tumors, acute myeloid leukemia, and acute lymphocytic 
leukemia are the most well-known malignancies associated with increased TLS and hospital 
mortality about 21%.80   
        Fructose metabolism could lead to elevated uric acid levels and gout risk due to purine 
nucleotide degradation or denovo purine synthesis. Also, fructose at a high concentration 
leads to lactic acid formation, causing blockages in urate elimination, resulting in HU. Thus 
there is an overt indication that the severity of HU-related fructose is dose-related.36,81 
Genetically, the variants in GLUT9, which is responsible for fructose transport, could 
increase the risk of gout flare in different multi-ethnicities.82 
        Sodium lactate infusion is administered to critically ill patients and yields benefits 
resulting in organ function improvement, specifically heart and brain, in ischemic 
situations.83 Nonetheless, lactate infusion could cause HU at high doses due to decreases in 
urinary fractional excretion of uric acid.84 
        Testosterone replacement therapy (TRT) is used for treating men who have gender 
identity disorder (GID) due to hypogonadism. TRT has shown several beneficial anabolic 
impacts on biological functions, including metabolism, cardio-protection, and enhanced bone 
and muscle cells synthesis.85,86 A recent study reported that dose-dependent TRT increases 
SU after three months of treatment (intramuscular injection of testosterone enanthate), with a 
29% to 43.4% increase after using 125 and 250 mg every two weeks.87 In addition, numerous 
studies have found that TRT induces gout disease 88. Hormonal replacement therapy could 
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affect gene expression. Hence, the therapy changes the level of urate transporters, causing 
HU due to a reduction in renal uric acid elimination. Additionally, because muscle is the 
major source of purine, increasing muscle mass during the early phases of therapy is linked to 
HU.63 
        There are also a variety of miscellaneous agents that could contribute to high uric acid 
levels, inducing HU and gout flare. Examples of these agents include acitretin, didanosine, 
ritonavir, filgrastim, L-dopa, omeprazole, peg-interferon, ribavirin sildenafil, teriparatide, 
ticagrelor, and topiramate. These agents have different mechanisms inducing HU, either 
through increasing uric acid production or decreasing urate elimination. Meanwhile, other 
agents such as teriparatide could lead to HU by creating an imbalance in endocrine function 
and thereby increasing serum parathyroid hormone levels, which are significantly associated 
with hyperuricemia (OR: 1.045; 95%CI: 1.017–1.075; P = 0.002).63,89  
        In short, several medications are associated with HU and gout flares due to different 
mechanisms of action. Additional studies are required to classify these pharmacological 
classes according to their severity in increasing uric acid levels from baseline to mild, 
moderate, and severe. 
Management of hyperuricemia and gout 
        It is usually accepted to define hyperuricemia when the uric acid level is above 7.0 
mg/dl. Meanwhile, the presence of HU without signs or symptoms of MSU crystal deposition 
is called asymptomatic hyperuricemia, linked to metabolic syndromes developments. 90 The 
goal of gout management is to prevent acute flare and prevent the complications that HU 
could cause. There are numerous pharmacological agents used in gout management, either in 
acute gout flare or in long-term management. These agents include nonsteroidal 
inflammatory drugs (NSAIDs), steroids, colchicine, and urate-lowering therapy (ULT). 
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Moreover, diet and social lifestyle changes could contribute to mitigating hyperuricemia 
complications and gout flare.91   
Management of acute gout flare 
         Acute gout flare is characterized by severe pain due to the deposition of MSU crystals 
in the joints.20 The primary purpose of treating acute gout is to reduce and resolve the pain 
associated with the flare. The drug choices used in clinical practice to manage gout flares 
consist of anti-inflammatory drugs, including non-steroid anti-inflammatory drugs (NSAIDs), 
colchicine, glucocorticoids (intra-articular, intramuscular, intravenous), as well as the 
incorporation of local ice therapy to decrease flare severity.92 Ibuprofen, indomethacin, and 
naproxen, classified as NSAIDs used to help relieve gout flare symptoms by inhibiting cyclo-
oxygenase enzyme (COX). Therefore, until the flare resolves, these drugs should be taken at 
the FDA-approved doses. Moreover, some NSAIDs, such as indomethacin, can also reduce 
SU due to uricosuric effects.93 Using NSAIDs in the long term may cause gastrointestinal 
bleeding in some patients; proton pump inhibitors could help minimize these side effects.94 
Colchicine is one of the effective medications used for an acute gout flare. Initiation of 
colchicine should be with a loading dose at 1.2 mg, followed by a 0.6 mg single dose after 
one hour, then continuous use of prophylactic doses of 0.6 mg once or twice a day, but not 
exceeding 1.6 mg/day to avoid toxicity.95 Colchicine is a cytochrome P450 and P-
glycoprotein substrate. As a result, it can interact with various drugs, including antineoplastic, 
macrolide antibiotics, and calcium channel blockers, potentially increasing colchicine toxicity 
(Table 1.4).96  
        Other options that could be used to treat an acute flare and decrease pain severity are 
steroids, either via intravenous or intra-articular administration. These options should be 
given with caution so as to avoid any complications related to steroid usage.97 Steroids such 
as oral prednisone, at a daily dose of 30 mg/d for 7 days, have been shown to be effective98 
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and are recommended by the ACR and EULAR panels as potential first-line therapy in the 
management of gout flares.99 Steroids are best administered in patients contra-indicated for 
NSAIDs or colchicine (i.e. CKD patients). When not contraindicated, co-prescription a low 
dose (0.5–1 mg/d) of colchicine may help prevent uncommon inflammation relapses after 
steroid discontinuation.20  
        Open-label studies also suggest that adrenocorticotropic hormone (ACTH) can relieve 
gout inflammation.100 Intra-articular steroid injections appear to be very effective and are 
recommended by both the ACR and the EULAR in the management of mono or poly-
articular flares, despite the lack of randomized clinical trials (RCT). Open-label studies of the 
IL-1 receptor antagonist anakinra support its off-label use in patients who are resistant or 
have a contraindication to NSAIDs, colchicine, and steroids. 101’102  
        Canakinumab agent is a long-acting antibody to IL-1 beta that is approved by the 
European Medical Agency following two RCT trials against intramuscular triamcinolone 
acetonide.103  The EULAR recommends considering IL-1 blockers for the management of 
gout flares in patients with frequent flares contraindicated to NSAIDs, colchicine, and 
steroids (oral or injectable).20  
Long-term management of gout 
        Urate lowering therapy (ULT) agents are used in long-term gout management to reach 
target uric acid levels within the normal range. The American College of Rheumatology 
(ACR) strongly recommends administering ULTs such as allopurinol for all patients with the 
presence of frequent acute flare at least once per year, chronic kidney disease stage 3 or 
higher, or history of nephrolithiasis in patients diagnosed with gout arthritis. Furthermore, it 
has been recommended that following a restricted diet and social life habits could help in 
gout management.104  
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        Allopurinol and its active metabolite, oxypurinol, are xanthine oxidase enzyme 
inhibitors that reduce uric acid production. The half-life of both allopurinol and oxypurinol 
are 1-2 and 15 hours, respectively, and both are excreted renally.105 When initiating ULT, it is 
important to provide gout prophylaxis to prevent ULT-induced gout flares. When the uric 
acid levels start to fall, the crystallization in the joints could shift, and this shift in the crystals 
may cause an acute gout flare. Thus, it is essential to continue gout prophylaxis for three to 
six months to avoid gout flares during UTL treatment. 106,107 Allopurinol dosage is 
determined on kidney function; thus, patients with normal kidney function should start at 100 
mg daily (but not more than 300 mg), with dose titration up to 50 mg every two to four weeks 
until the target uric acid level is achieved.105 Patients who suffer from renal function decline 
should be started on allopurinol 50 mg, followed by a titration up to 50 mg every two to five 
weeks until the uric acid levels reach the normal range.96  
        Although allopurinol hypersensitivity syndrome is uncommon, it could occur in some 
patients, notably in the elderly with renal impairment, patients using a thiazide diuretic, and 
some Asian groups with HLA-B* 5801 genotypes. Thus, ACR recommends using alternative 
ULTs in the Asian ethnic population who have tested positive for the HLA-B* genotype so as 
to avoid allopurinol hypersensitivity syndrome, leading to Stevens-Johnson syndrome or 
toxic epidermal necrolysis. These major adverse effects are characterized by vasculitis, 
hepatocellular and acute kidney injury, fever, leukocytosis, and eosinophilia. Therefore, the 
initial dose in normal and decreasing renal function patients should be less than 100 mg and 
50 mg, respectively, to reduce the risk of allopurinol hypersensitivity. 105,108  
        The FDA approved Febuxostat in February 2009 for the treatment of chronic gout 
patients. Febuxostat is a non-purine selective xanthine oxidase inhibitor. The half-life of 
febuxostat is about five to eight hours, and it is metabolized mainly by the liver and 
eliminated by renal and hepatic routes.109 Compared to allopurinol, with respect to its safety 
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profile, febuxostat is associated with increased cardiovascular-related mortality; therefore, the 
FDA recommends minimizing its use only in patients who do not derive any benefits from 
allopurinol or who have serious side effects from allopurinol use. Therefore, before switching 
from allopurinol to other xanthine oxidase inhibitor agents, allopurinol should be titrated to 
the maximum tolerable dose possible.110  
        Febuxostat is a once-daily pill available in multiple doses, available in 40 and 80 mg 
doses in the USA and 80 and 120 mg doses in Europe. Febuxostat is a more effective ULT 
than allopurinol at dosages of 80 and 120 mg/d (maximum levels authorized in the United 
States and Europe, respectively). 111 Febuxostat is contraindicated in patients diagnosed with 
CVD, including ischemic heart disease and congestive heart failure. In addition, febuxostat is 
more costly than allopurinol.96 Moreover, febuxostat is associated with elevated liver 
enzymes compared with allopurinol, and it can cause adverse drug reactions such as nausea, 
arthralgia, and rashes.109 
        Uricosuric medications such as probenecid and benzbromarone are pharmacological 
agents used to facilitate uric acid excretion in order to achieve the target urate levels. 
Probenecid is an appropriate adjunctive or second-line therapy for preventing acute flare by 
inhibiting the renal excretion of organic anions in the proximal renal tubule and reducing 
tubular urate reabsorption.96 The use of probenecid is recommended as a ULT in gout if 
allopurinol is ineffective or contraindicated. Using probenecid as a ULT monotherapy is rare. 
However, the use of probenecid in combination with allopurinol results in a significant 
reduction in uric acid levels.112 Benzbromarone is more effective than probenecid uricosuric 
agent, but it is infrequently used due to hepatotoxicity. Thus, it is restricted only to patients 
who cannot tolerate other ULT agents.113 Furthermore, patients who suffer from kidney 
stones, renal impairment, or who indicate the presence of uricosuria (higher than 700 to 800 
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mg/24 hours) must avoid these uricosuric agents.92 Other pharmacological agents including 
losartan and fenofibrate show a uricosuric effect, but it is not a class-wide effect.114 
        Pegloticase is another option that could be used for the treatment of chronic tophaceous 
gout cases. It can be used if the patient cannot take the available conventional urate-lowering 
drugs such as allopurinol, febuxostat, or probenecid. Pegloticase is a potent ULT and could 
improve the quality of life in patients with tophaceous gout by reducing the size and severity 
of urate tophi.115 From a pharmacological perspective, pegloticase is a human recombinant 
enzyme that helps to convert uric acid into allantoin, which is more soluble and easier to 
excrete.116 However, pegloticase has several adverse drug reactions, including anaphylactic 
symptoms related to infusion administration.117 Moreover, pegloticase is contraindicated in 
special ancestral groups such as Africans and Middle Easterners with glucose-6 phosphate 
dehydrogenase (G6PD) deficiency.118  
        In summary, in this chapter, we have discussed the whole prospective of HU/gout 
prevalence. Published reports afford us multiple opportunities to investigate other reasons for 
HU/gout prevalence between different races. Therefore, we decided to assess the urate 
transportome genetic polymorphism across the different societies in the US. The main goal is 
to take the first step into personalized medicine in order to minimize health inequalities 









Table 1.1: Uric acid normal range1 
Gender mg/dl 
Males, postmenopausal women 3.5 – 7.2 















All 3.9 (3.2, 4.7) 20.1 (17.8, 22.4) 9.2 million 
Male 5.2 (4.4, 6.2) 20.2 (16.6,24.3) 5.9 million 
Female 2.7 (2.0, 3.8) 20.0 (17.8, 22.4) 3.3 million 
Caucasian 4.0 (3.1, 5.3) 21.4 (18.1, 25.1) 6.13 million 
African American 4.8 (3.8, 6.0) 22.6 (20.9, 24.3) 1.3 million 

















Table 1.3:Gout Comorbidities 62 
Organ system  Clinical condition  
Cardiovascular Hypertension 




Peripheral vascular disease 
Atrial fibrillation 
Thromboembolism 






Neurological Alzheimer’s disease 
Vascular dementia 
Parkinson’s disease 
Ophthalmological  Macular degeneration 












Table 1.4: Common drugs that interact with colchicine 96 
Strong CYP3A4 inhibitors Moderate CYP3A4 
inhibitors 
P-glycoprotein inhibitors 
Clarithromycin Cimetidine Amiodarone 
Cobicistat Ciprofloxacin Carvedilol 
Diltiazem Cyclosporine Clarithromycin 
Itraconazole Erythromycin Itraconazole 
Ketoconazole Fluconazole Quinidine 
Ritonavir Fluvoxamine Ranolazine 
Telithromycin Imatinib Ritonavir 




















Figure 1.3: Uric acid and cardio metabolic diseases55 
 
(NAFLD): Non-alcoholic fatty liver disease, (RAAS): Renin-Angiotensin-Aldosterone 
system
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Chapter 2: Genetic Assessment of Hyperuricemia and Gout in Asian, Native 
Hawaiian, and Pacific Islander Subgroups of Pregnant Women: Biospecimens 
Repository Cross-Sectional Study 
 



















Gout, an inflammatory condition, is characterized by the precipitation of monosodium 
urate crystals (MSU) in or around joints. The latter is caused by chronic hyperuricemia 
(HU) - high urate levels in the blood. Genetic variations in urate transporters play a 
significant role in regulating urate levels within the human body, rendering some racial 
and ethnic groups more susceptible to developing HU or gout. This study aims to 
estimate the frequencies of HU and gout risk alleles in Asian, Native Hawaiian, and 
Pacific Islander subgroups using biorepository DNA samples. Urate allele frequencies 
in Japanese, Korean, Filipino, Native Hawaiian, Samoan, and Marshallese were then 
compared with Europeans (EUR).  
 
Methods: 
The biospecimens repository center at the University of Hawaii provided DNA samples 
of consented post-partum women. The DNA was extracted from the cord blood and 
genotyped at the Genomics and Bioinformatics Shared Resource, Cancer Center 
(Honolulu, HI). Nine urate genes: ABCG2, SLC2A9, SLC16A9, GCKR, SLC22A11, 
SLC22A12, LRR16A, PDZK1, and SLC17A1, were selected due to their significant 
association with HU and gout risk. Hardy-Weinberg equilibrium (HWE) for genotype 
frequencies was assessed using the Chi-Square test with p<0.05 for statistical 
significance. Allele frequencies in our study were compared to EUR from the 1000 
Genomes Project Phase 3 database, using the Chi-square or Fisher exact test as 
appropriate. Bonferroni correction for multiple comparisons was used, with p<0.006 for 
statistical significance.  
Results: 
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Our study involved 1095 post-partum women 18-year-old or older who self-reported 
their respective race and ethnicity, including Asian and Pacific Islander ancestry. Asian 
groups involved Korean, Japanese, and Filipino. Besides, the Pacific Islander group 
includes Native Hawaiian, Marshallese, and Samoan. None of the study participants had 
a history of gout. We excluded the PDZK1 gene from the final analysis due to its 
deviation from HWE (p<0.05) across all the populations. Compared to EUR, the genetic 
polymorphism frequencies were significantly different-8/8 in Japanese, 6/8 in Korean, 
6/8 in Filipino, 8/8 in Samoan, 6/8 in Hawaiian, and 6/8 in Marshallese. The total count 
of HU and gout risk alleles between our participants and EUR were 8, 5, 6, 5, 4, and 4 
in Japanese, Korean, Filipinos, Samoans, Marshallese, and Hawaiians, respectively. The 
percentage of cumulative risk alleles was 100% in Japanese and Filipino followed by 
83.5% in Korean.  
Conclusions: 
Compared to EUR, Asian subgroups, particularly Japanese, Filipinos had the highest 
percentage of UA risk alleles at 100%, followed by Koreans at 83.5%. These results 
could partly explain that some individuals of Asian descent are at an increased risk of 
developing HU or gout.  
Keywords: Gout, Hyperuricemia, Health Disparities, Genetics, Asian Ancestry, Native 
Hawaiians, Pacific Islanders, Single nucleotide polymorphisms, Pregnancy
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Introduction 
        Gout is an inflammatory arthritic condition characterized by the precipitation of 
monosodium urate crystals (MSU) in or around distal joints.1 Chronically elevated 
serum urate (SU), a condition known as hyperuricemia (HU), is the culprit of 
developing gout. Acute gout flares affect monoarticular joints (e.g., knees, ankles, and 
metatarsophalangeals), causing severe inflammation marked with excruciating pain, 
swelling, erythema, and reduced mobility.20 The prevalence of gout in developed 
countries is higher than the developing ones. In the United States (U.S.), gout 
prevalence is up to 3.9%, affecting about 9.2 million people.11 Gout and hyperuricemia 
prevalence varies by sex and age groups. Also, specific racial and ethnic subgroups 
have distinct HU and gout prevalence, ushering the notion of population-specific risk 
and suggesting distinct HU and gout risk allele frequencies across different racial and 
ethnic groups.36  
        Many factors play  significant roles in regulating SU levels and might lead to HU 
and gout.119 Genetic polymorphisms in uric acid transporters, mainly single nucleotide 
polymorphisms (SNPs), have been implicated in developing HU or gout. Numerous 
studies have ascertained the role of the genetic variation of urate transporters, and 
estimate the heritability of urate is up to 73%.22 One of the largest genome-wide 
association studies (GWAS) metanalysis, involving more than 110,000 participants 
from different racial backgrounds, discovered 28 loci associated with SU levels.23 These 
loci are predominately in genes encoding urate transporters, including SLC2A9, ABCG2, 
SLC22A11, SLC22A12, SLC17A1, and the scaffolding protein-encoding gene PDZK1.22  
Indeed, the prevalence of and HU gout varies among people and countries. Along with 
differences in the genetic background, several demographic and environmental 
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characteristics such as diet and lifestyle, smoking, alcohol consumption, or beverages 
containing high amounts of fructose may increase prevalence.120   
        Studies published in 2015 and thereafter showed substantial increase in gout 
incidence over recent decades in the U.S., Canada, Denmark, Sweden, and South Korea, 
confirming greater incidence in men relative to women, and increased incidence in later 
life decades. Besides, recent studies in North America and Scandinavia found a 1.5–2-
fold increase in gout incidence over the past two to three decades.116,121–125 Gout 
incidence in South Korea increased by 25% between 2009 and 2015.10 A recent study 
reported that the Maori and Pacific Islanders groups in New Zealand have a gout 
prevalence of 7.6%.126 These trends indicate that gout incidence increased in many 
countries over recent decades and that the aging population in these countries may drive 
this increased gout incidence. Gout prevalence varies globally, with Oceanic countries 
having one of the highest prevalence worldwide, particularly in indigenous and South 
Pacific Island populations. Along with the earlier reported increasing prevalence of gout 
in Europe and the US, there is evidence of increasing prevalence in Australia (self-
reported), Canada, China, and South Korea as well.15 According to the U.S. Census 
Bureau, Chinese and Filipino communities are considered the largest Asian subgroups. 
Similarly, Native Hawaiians and Samoans are the largest Pacific Islander subgroups.127 
Amongst all the ethnic subgroups in the U.S., populations with Asian ancestry are 
approximately three times more likely to develop gout than Europeans (EUR).128 
Despite the correlation between genetic polymorphisms in urate disposition and 
incidence of gout amongst different ethnic groups, the frequencies of HU and gout risk 
alleles in a low admixed subgroups remain unknown. Therefore, the purpose of this 
study is to estimate the frequencies of selected SNPs in essential urate genes across 
diverse populations rarely represented in genetic or clinical research (Filipino, Japanese, 
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Korean, Samoan, Marshallese, and Native Hawaiian) compared with EUR. With the 
growing need for racial diversity in genomic research, this study will further our 
understanding of the genetics of HU and gout in underrepresented minorities. 
Furthermore, to establish the genetic basis between ethnicity and gout prevalence. We 
hypothesized that the risk allele frequencies of HU and gout significantly differ between 
the Asian, Native Hawaiian, and Pacific Islander subgroups compared to European 
(EUR) population.   
Methods 
Study participant and urate genes 
        Participants included in this study were pregnant women who are 18-year-old or 
older. All participants self-reported 100 % of their respective race/ethnicity, indicated 
by both biological parents and four grandparents being of the same race/ethnicity. We 
excluded any participants age <18 years old, with a history of cancer or organ 
transplant, and poor DNA quality in the final analysis. The uric acid gene/SNPs were: 
SLC17A1 (rs1183201), PDZK1 (rs12129861), SLC22A11 (rs17300741), ABCG2 
(rs2231142), SLC16A9 (rs2242206), SLC22A12 (rs505802), SLC2A9 (rs734553), 
LRRC16A (rs742132), GCKR (rs780094).  
Sample procurement and genotyping 
        DNA samples along with medical and demographics information of study 
participants were provided by the University of Hawaii biospecimens repository. 
Historically, these samples were collected after obtaining the written consent. The 
placenta and umbilical cord of the participants were collected as part of the routine care. 
DNA extraction was from cord blood samples and genotyping was carried out at the 
Genomics and Bioinformatics Shared Resource, Cancer Center (Honolulu, HI). A 
customized TaqMan genotyping assay panel was run on the Quant Studio 12K Flex 
 31 
Real-Time PCR system (Applied Biosystems). All study details were previously 
published.129 All study material were reviewed and exempted by the University of 
Hawaii Human Studies Program (protocol Number: 2018-00225). 
Statistical analysis 
        The data analysis was conducted utilizing SPSS Statistics for Windows, version 23 
(IBM SPSS, IBM Corp., Armonk, N.Y., USA). Shapiro – Wilk test was used to 
evaluate normal distribution for continuous variables. Demographic characteristics were 
expressed as means (+/- standard deviation and minimum-maximum) for parametric 
data and number (%) for categorized data. Allele frequencies in our data were compared 
with EUR, using Chi-square or Fisher’s exact test, when appropriate. Bonferroni 
correction was used for multiple comparisons with p <0.006 for statistical significance. 
Deviation from Hardy-Weinberg Equilibrium in our selected genetic polymorphisms 
was assessed using Chi-square test with P<0.05 for statistical significance. Ensemble 
genome browser was used to estimate the allele and genotype frequencies of EUR 
population (Reference). In our study, the risk allele was defined as the allele associated 
with the baseline or higher risks of developing HU and/or gout. 
Results 
        Study participants characteristics and demographics in this study, 1059 participants 
were included. Demographic characteristics of all participants are shown in Table 2.1. 
The participant’s age ranged from 18 to 47 years with a means of 29 years. The 
gestational age ranged from 24 to 41 weeks with a means of 38 weeks, of which 82.2% 
(n= 871) were full term and 17.3% (n= 182) were pre-term. Using the pregravida 
weight, the body mass index (BMI) ranged from 24.5 to 30.1 kg/m2, with mean of 26.3 
kg/m2, of which 43.4% (n= 400) were classified as having normal weight, 26.9% (n= 
248) were classified as obese, 22.9% (n =211) were classified as overweight, and 6.8% 
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(n= 63) were classified as underweight. It is worth mentioning that Asian and Asian 
Americans are at high risk of obesity at lower BMI than in whites.130 Our study 
consisted of 21.5%. (n= 229) Filipinos, 19.8% (n= 210) Japanese, 18.9% (n= 200) 
Samoans, 15.1% (n= 160) Marshallese, 14.7% (n=156) Hawaiian, and 9.8% (n= 104) 
were Koreans. No subjects reported a history of gout. 
 
Genetic Analysis and Quality Control 
        As a measure of quality control, genetic results were assessed for Hardy-Weinberg 
Equilibrium (HWE), using chi-square with p<0.05 for significance (Table 2.6). SNPs 
call rates were evaluated and reported for each ethnic group and for the overall study 
cohort (n=1059 participants). Overall SNPs call rate were 97.4% in SLC22A12, 95.1% 
in SLC17A1, 96% in SLC16A9, 96.9% in ABCG2, 94.3 in SLC22A11, 91% in PDZK1, 
96.1% in SLC2A9, 96.4% in LRRC16A, and 96.7% in GCKR (Table 2.7). 
Hyperuricemia and Gout Risk Alleles Frequencies 
        Risk alleles and genotype frequencies of all nine uric acid genes/SNPs in all ethnic 
subgroups are summarized in Table 2.3 & Table 2.4. Due to deviation from the HWE, 
we excluded the rs12129861 C>T in PDZK1 from the final analysis. In the Japanese 
group, eight out of the eight uric acid SNPs were significantly different from EUR 
(Table 2.5). All these eight alleles (100%) were prevalent in the Japanese population 
from EUR and were considered risk alleles. These risk alleles included: rs1183201 T>A 
in SLC17A1, rs2231142 G>T in ABCG2, rs2242206 G>T in SLC16A9, rs505802 C>T 
in SLC22A12, rs734553 G>T in SLC2A9, rs17300741 A>G in SLC22A11, rs742132 
A>G in LRRC16A, and rs780094 C>T in GCKR. 
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        In the Korean group, six out of the eight uric acid SNPs were significantly different 
from EUR (Table 2.5). Five out of the six alleles (83.5%) were more prevalence in 
Koreans than EUR and were considered risk alleles. These risk alleles genes/SNPs 
included: rs1183201 T>A in SLC17A1, rs2242206 G>T in SLC16A9, rs505802 C>T in 
SLC22A12, rs734553 G>T in SLC2A9, rs17300741 A>G in SLC22A11. 
In the Filipino group, six out of the eight uric acid SNPs were significantly different 
than those of EUR (Table 2.5). All these six SNPs in Filipino were more prevalent 
(100%) than EUR. These genes/SNPs included: rs1183201 T> A in SLC17A1, 
rs2231142 G>T in ABCG2, rs2242206 G>T in ABCG2, rs2242206 G>T in 
SLC16A9, rs505802 C>T in SLC22A12, rs734553 G>T in SLC2A9, and rs17300741 
A>G in SLC22A11. 
        In the Marshallese group, six out of the eight uric acid SNPs were significantly 
different in the Marshallese population than those of EUR (Table 2.5). Among those six 
SNPs, the Marshallese population had four uric acid alleles significantly more prevalent 
(66.5%) than EUR. These genes/SNPs included: rs2231142 G>T in ABCG2, rs2242206 
G>T in SLC16A9, rs505802 C>T in SLC22A12, and rs734553 G>T in SLC2A9. 
In the Samoan population, eight out of the eight urate SNPs were significantly different 
from EUR (Table 2.5). Among those eight SNPs, five uric acid alleles (62.5%) had a 
higher prevalence in the Samoan population than EUR. These genes/SNPs 
included: rs2231142 G>T in ABCG2, rs505802 C>T in SLC22A12, rs734553 G>T in 
SLC2A9, rs17300741 A>G in SLC22A11, rs1183201 T>A in SLC17A1. 
        In the Native Hawaiian group, six out of the eight uric acid SNPs were 
significantly different from EUR (Table 2.5). Four out of six alleles (66.5%) were more 
prevalence in Native Hawaiian population than EUR and were considered risk alleles. 
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These genes/SNPs include:  rs505802 C>T in SLC22A12, rs734553 G> T in SLC2A9, 
rs17300741 A> G in SLC22A11, and rs1183201 T>A in SLC17A. 
        Among all our studied population subgroups, Asian subgroups of Japanese, 
Koreans, and Filipinos had the highest HU and gout risk allele indices of 8, 5, and 6, 
respectively. The percentages of risk alleles were 100% in Japanese and Filipino, 
followed by 83.5% in the Korean subgroup. Pacific Islander subgroups were 66.5% in 
Native Hawaiians and Marshallese, followed by 62.5% in Samoan (Table 2.5).  
Discussion 
        Our study found that the population of Asian ancestry had a higher prevalence of 
HU and/or gout risk alleles compared with the EUR population. Uric acid associated 
alleles found in the Asian subgroup were significantly different from the EUR 
population and were all considered HU and/or gout risk allele. These results could 
partially explain the differential prevalence of hyperuricemia and gout across different 
ethnic and racial groups based on their genetic makeup. Therefore, a discussion on the 
role of these various genes/alleles in developing HU and/gout is warranted.  
ABCG2 gene encodes the ATP-Binding Cassette G-protein transporter located in the 
apical membrane in the proximal renal tubule, and it is also expressed in the 
gastrointestinal tract and liver. ABCG2 is a major urate excretion transporter.131 Genetic 
polymorphisms in the ABCG2 gene were reported to contribute to elevated urate levels 
leading to hyperuricemia and gout. The SNP rs2231142 G>T (Q131K) in ABCG2 is 
associated with increased urate levels in the presence of the T-allele.131 Therefore, 
individuals with the TT genotype are at high risk of HU and gout than GG counterparts. 
A recent study reported that T-allele presence is 3- times higher in East Asians than 
EUR. This suggests that East Asian populations are at higher risk for developing HU 
and gout.132 
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        Similarly, our findings showed that the prevalence of the T allele of the rs2231142 
(G>T) was 9.4% in EUR, 45.8% in Filipinos, 27.8% in Koreans, and 25.6% in Japanese 
(Table 2.3). In our Korean cohort, however, the rs2231142 (G>T) deviated from the 
HWE (p=0.0407) (Table 2.6). In the Native Hawaiian and Pacific Islander (NHPI) 
subgroups, the frequencies of the T allele of the rs2231142 (G>T) were 31.1%, 17.6%, 
and 12.7% in Samoan, Marshallese, and Native Hawaiian subgroups, respectively. The 
genetic polymorphism rs22131142 (G>T) in ABCG2  is significantly associated with 
urate levels and increased risk for HU and gout among different populations.34,133,134  
A study conducted in the Korean population showed that the rs22131142 G>T is 
strongly associated with gout risk (Odds ratio [OR] 3.32; 95% confidence interval [CI]: 
2.11 to 5.20).135 Also, in a study of 6881 Koreans identified that the genetic 
polymorphism rs2231142 (G>T) was associated with increased SU levels (Effect size = 
0.220, p=2.06E-29).136  Consistent with our results,  a previous study reported that the 
minor allele frequency (MAF) of the T risk allele of the genetic variant rs2231142 
in ABCG2 was high in Japanese and Koreans compared to Caucasians (0.29, 0.28, vs. 
0.11).137 Additionally, a meta-analysis conducted on a multi-ethnic cohort reported that 
the T allele of rs22131142 G>T in ABCG2 was strongly associated with HU and gout 
across populations, and the severity is affected by gender and ethnicity.138   
Overall, the genetic polymorphism rs2231142 (G>T) of the ABCG2 gene is considered 
the most significant gene polymorphism related to the increased risk of HU and/or gout 
in selected minorities compared with other risk alleles. Sun et al. studied the association 
between 11 genetic loci of which ABCG2 rs2231142 (G>T) was one of the genes 
associated with serum urate concentrations in the Chinese population.139 Also, Zhang et 
al. reported that the SNP rs2231142 of the ABCG2 gene was associated with 
hyperuricemia in the American population consisting of EUR Americans, African 
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Americans, Mexican Americans, and Indian Americans.140  Our finding provides that 
the genetic variants in ABCG2 rs2231142 (G>T) may increase urate levels and gout risk 
in Asian, Native Hawaiian, and Pacific Islander subgroups compared to EUR.  
        SLC2A9 encodes the GLUT9 transporter, which has a high-capacity transporter for 
urate, fructose, and glucose. It is known to be strongly associated with urate regulation 
in the human body.141  It is mainly expressed in the kidneys and liver, but it is also 
expressed in human articular cartilage.142 The intronic polymorphism rs734553 (G>T) 
in SLC2A9 is associated with increased HU risk and gout resulting from a change in 
transporter affinity for urate.143  This genetic variation strongly affects SU levels in 
EUR ancestry and could significantly affect SU in women (Effect size = 0.315, 
p=5.22x10-201).32  Reginato Am et al. have identified that polymorphism rs734553 of 
the SLC2A9 gene is linked to SU levels and gout in the Islandic Polynesian 
population.144  
        Our analysis has shown that the T-allele's prevalence in Asian and Pacific Islander 
populations was higher than in the EUR population. Specifically, the frequency of 
rs734553 (G>T) was 99.5% in Japanese, 98.8% in Filipinos, and 98.3% in Koreans 
compared to 75.5% in EUR (p<0.0001). Additionally, the frequency of rs734553 (G>T) 
was 100% in Marshallese, 98.3% in Samoans, and 90.9% in Hawaiians compared to 
75.5% in EUR (p<0.006) (Table 2.3). Our results suggest that carrying the T -allele will 
likely increase the risk of elevated SU in both the Asian and NHPI subgroups.  
SLC17A1 encodes the voltage-gated human sodium-dependent phosphate co-transporter 
type 1 protein (NPT1), located in the proximal tubule's apical side in the kidney and 
works as renal urate efflux transporter. Decreased SU Levels were found to be 
associated with the genetic polymorphism rs1183201 (T>A) in SLC17A1 (Effect size = 
-0.062, 95% CI: -0.078; -0.459) with the effect of allele A as the protective allele of 
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EUR descent. Therefore, intronic SNP rs1183201 (T>A) of SLC17A1, the A allele, was 
associated with decreased SU level with a prevalence of 48.2% in EUR descent. In the 
intronic SNP rs1183201 (T>A) of SLC17A1, the A allele was associated with decreased 
SU level with a prevalence of 48.2% in EUR descent.32  The polymorphism rs1165205 
of SLC17A3 has strong linkage disequilibrium r2=0.966 with rs1183201of SLC17A1 
and has shown an association with gout and SU in Korean population with a MAF of T 
allele of 0.137.137  
        Our analysis found that the prevalence of A allele in both Asian and Pacific 
Islander populations was lower than EUR descent except in Marshallese, where it was 
57.2% vs. 46.1% (p=0.002). Amongst the Asian population, the frequency of A allele 
for rs1183201 (T>A) was 2-3-folds lower than that observed in EUR (14.6%, 17.1%, 
and 20.9% for Koreans, Japanese, and Filipinos respectively vs. 46.1% p<0.00001) 
(Table 2.3). The significant differences in A allele frequency across minorities covered 
in our study suggest that some ethnicities could be genetically predisposed to high urate 
levels. 
 
        SLC22A12 encodes for URAT1, a protein found on the kidney's apical side of the 
proximal tubules. This transporter is responsible for the majority of the urate 
reabsorption from the kidneys and a primary target for urate-lowering therapies.145  A 
previous study reported that the loss of activity in URAT1 had been found to cause 
hypouricemia in Japanese populations, suggesting that URAT1 plays an essential role in 
regulating the renal tubular reabsorption of urate.146  The intergenic polymorphism 
rs505802 (C>T) in SLC22A12 was observed to reduce urate levels in EUR ancestry. 
Specifically, the T- allele correlates with lower SU levels in women and men (Beta 
effect -0.073, -0.047, respectively) in EURs.32  
 38 
        Jang et al. reported that the T6092C genetic variant of SLC22A12 was also 
significantly associated with SU concentration amongst the male Korean population.147 
The T6092C at rs1529909 of SLC22A12 was found in linkage disequilibrium (LD= 1, r2 
=1) with rs505802 of SLC22A12. However, the prevalence of the T-allele in our 
population subgroups was lower than EUR population (p<0.00001). Our results found 
that the prevalence of T-alleles was 3-4-folds lower in both Asian and NHPI 
populations (Table 2.3), which suggests a higher baseline line urate levels in the Asian 
and NHPI population subgroups compared with EURs. Furthermore, our findings 
showed that the C-allele frequency was higher in both subgroups of targeted 
populations compared with EUR. Particularly, the frequency of the C allele in 
Marshallese was more than three times than EUR (95% vs. 29.3%, p<0.00001). These 
results propose a higher risk for HU and/or gout in our studied populations and suggest 
a possible implication in the response to treatments targeting URAT1 transporter in 
Asian and NHPI subgroups.  
 
        SLC22A11 is predominantly expressed in the proximal tubule's apical side in the 
kidney and encodes the organic anion transporter 4 (OAT4). The Organic anion 
transporter 4 (OAT4) is associated with regulating UA reabsorption, like URAT1, and a 
target for urate-lowering therapy.148 The intronic variant rs17300741 (A>G) in the 
SLC22A11 gene was associated with renal urate under excretion type gout in the 
Japanese population (p=0.049).149  Kolz et al. have reported a significant association 
between the polymorphism in OAT4/SLC22A11 rs17300741 A>G and UA levels in 
individuals of Caucasian descent (p = 6.7×10−14).32 Our analysis found that the A-
allele prevalence was higher across selected minorities than EUR. The A allele 
frequency in the Asian subgroups of Koreans, Filipinos, and Japanese, was about 2-fold 
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higher than EUR (89.6%, 85.3%, and 84.7%, respectively vs. 46.2% in EUR 
(p<0.00001). Furthermore, the A allele frequency was higher in Samoan, Native 
Hawaiian, and Marshallese compared with EUR (78.5%, 72.3%, and 70%, respectively, 
vs. 46.2% in EUR (p<0.00001). Our analysis of the rs17300741 A>G in SLC22A11 
suggests a higher genetic risk for higher baseline urate levels or gout in Asian and NHPI 
compared with EUR. Hence, our results are consistent with the previous literature 
confirming the association of rs17300741 A>G with the prevalence of gout, which is 
two-fold higher in non-EURs relative to EURs.150 Collectively, our study shows that the 
frequencies of risk alleles C and A in both loci SLC22A12 and SLC22A11, 
respectively, were significantly higher in Filipino, Korean, Japanese, Samoan, 
Marshallese, and Native Hawaiian relative to EUR (Table 2.3). Notably, the prevalence 
of risk alleles rs505802 (C>T) of SLC22A12 and rs17300741 (A>G) of SLC22A11 
genes were highest in Asian subgroups compared with the NHPI population. 
 
        SLC16A9 encodes for monocarboxylic acid transporter protein across the cell 
membrane (MCT9). It is located on the proximal tubule's apical side of the kidney and 
responsible for urate excretion. A missense variant rs2242206 (G>T) in the SLC16A9 
has been reported to dysregulate urate level. Nonetheless, Nakayama et al. have found a 
significant relationship between the rs2242206 G>T (K258T) in SLC16A9, and gout 
(p = 0.012), with an odds ratio (OR) of 1.28 in a Japanese population.151 Our cohort 
analysis showed that the frequency of T allele across minority subgroups was 
significantly higher than that of EUR ancestry (Table 2.3). 
        Remarkably, the Asian subgroup (Koreans, Japanese, and Filipinos) had the 
highest prevalence of T allele, which is approximately two times higher vs. EUR 
(59.2%, 55.5%, and 45%, respectively, vs.26.6%, p<0.00001). Additionally, the 
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prevalence of risk allele T in Native Hawaiians (45.1%), Marshallese (44.5%), and 
Samoans (39.3%) were significantly higher compared with EUR (26.6%) (p<0.00001). 
However, the polymorphism rs2242206 (G>T) in the SLC16A9 was not in HWE in 
Samoans and Hawaiians (Table 2.6). These findings suggest that individuals of Asian 
descent, carrying the polymorphism in rs2242206 (G>T) in SLC16A9 could be at higher 
risk for and an increase the susceptibility to gout, especially in individuals of Japanese, 
Korean, and Filipino descent. 
 
        GCKR is a protein that encodes glucokinase regulatory protein (GCKR), which has 
a role in developing the metabolic syndrome, involving triglyceride regulation and 
glucose metabolism.152,153 Several studies have shown the relationship between urate 
levels and metabolic syndrome-related traits such as insulin resistance and hypertension 
through oxidative stress and inflammatory pathway.32  The intronic variant rs780094 
(C>T) of the GCKR gene has shown a strong association with gout in the male Han-
Chinese population.154  Furthermore, the T- allele of Intronic polymorphism 
of rs780094 C>T has been associated with UA concentration regulation in EUR 
ancestry.32 Meanwhile, the MAF of the C allele was higher in the Korean group 
compared with Caucasian ancestry (0.47, vs. 0.42).137  
 In our analysis, the frequency of T-allele was higher in the Japanese subgroup than 
EUR (58% vs. 41.1%, p<0.00001) and lower in Samoans than EUR (30.6 vs. 41.1%, 
p=0.0005) (Table 2.3). This signifies that allele is associated with less risk for HU 
and/or gout. There was no significant difference between Filipinos and Koreans 
compared to EUR, although the T-allele frequency was higher in Asian subgroup 
ancestry. Overall, these results found that the Japanese subgroup could be predisposed 
to developing HU and gout compared with other subgroups in the study. Noteworthy, 
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GCKR protein is associated with modulating the metabolic activities; hence, this finding 
might partially suggest a biological mechanism between genetic variations and the 
development of cardiometabolic disorders, including HU and gout, which may 
contribute to the health disparities seen in gestational diabetes and hypertension in 
pregnant women.  
 
        PDZK1 has been identified in the kidney and acts as a scaffolding protein for 
different transporter proteins associated with SU levels baseline.155  The Intergenic 
variants rs12129861 (C>T) of PDZK1 protein have shown an association with reducing 
the risk of gout in the male Han-Chinese population (OR = 0.727, P =0.015).155 Kolz et 
al. have identified the role of scaffolding PDZK1 protein in SU baseline regulation.32  
It should be noted that we found a deviation when we conducted the Hardy-Weinberg 
equilibrium investigation PDZK1 rs12129861 (C>T) genotypes across all minorities 
addressed in the study (p<0.05) (Table 2.6). In this case, further studies having a larger 
sample size and different ethnic backgrounds are needed to investigate the prevalence of 
risk alleles to validate our results. Hence, we excluded this protein from the results of 
this study to avoid any conflicts in our findings.  In genetic science, the Hardy 
Weinberg equilibrium principle applies to estimate if the allele and genotype 
frequencies remain constant from generation to the next. Several factors may influence 
HWE, and the technical issues in the genotyping sequencing consider one of them.156 In 
our dataset, the PDZK1 across the whole population deviated from HWE, and we 
assume a lab error happened during genotyping. 
 
        LRR16A is expressed in the apical side of proximal tubules in the kidneys, which 
encodes a protein called capping protein ARP2/3 and myosin-I linker (CARMIL). This 
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protein has a role in urate transportome formation, which mediates urate 
reabsorption.32,157  Hiraka Ogata et al. have found a significant association between 
intergenic variant homozygote AA in rs742132 A>G of LRRC16A and risk of gout 
disease among Japanese males.158  
The genetic polymorphism rs742132 in LRRC16A is associated with increased SU in 
EUR ancestry.32 Notably, a GWAS study conducted on East Asian groups, including 
Koreans, showed that the rs742132  in LRRC16A is associated with elevated urate 
levels.159 Our analysis showed that Japanese had a higher frequency of the A-
allele compared to EUR (78.2%, vs. 69%, p=0.0009). However, the frequency of the A-
allele in the Filipinos was indifferent compared with EUR (69.7% vs. 69, p=0.836). In 
addition, Koreans had an insignificantly different A-allele frequency compared with 
EUR (78%, vs. 69, p=0.017).  On the other hand, in NHPI groups, there was a deviation 
from Hardy-Weinberg equilibrium in the Native Hawaiians p<0.05 (Table 2.6). Also, 
although the prevalence of A-allele in Marshallese was higher than EUR, it was not 
statistically significant (70%, vs. 69%, p=0.819) (Table 2.3). Moreover, Samoans had a 
lower frequency of the A-allele compared with EUR (51.7%, vs. 69%, 
p<0.00001) (Table 2.3).  Asian subgroups of Japanese and Koreans had the highest A-
allele frequency as compared to the other subgroups in this study, and this is consistent 
with other results in the literature.160 Our findings suggest that the genetic 
polymorphism in rs742132 of LRRC16A may explain the differential prevalence of 
HU/gout across different population’s subgroups. 
        Collectively, our results have shown that the frequency of HU and/or gout risk 
alleles in several population subgroups significantly differs from EUR (p<0.006). We 
found out that the Asian subgroups had the highest prevalence of HU and/or gout risk 
alleles as compared to the NHPI populations. These results are consistent with the 
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patient claims data in the ambulatory care clinics that gout diagnosis in the Asian 
population living in the U.S. is about three times more than EUR (reference).  
Consistent with the previously published reports , our results provide more evidence 
that populations of Asian descent have a higher risk of developing HU and/or gout than 
EUR.34,161,162   
 
Limitations 
        We have several limitations in this study. First, this study was retrospective, and 
the participants were selected from one location. Hence the sample size may not be 
representative of all populations. In addition, in retrospective studies, the medical 
records system provides information, and those datasets are obtained in a pre-designed 
form that may not match the study's purposes. Therefore, some data would constantly be 
missing. Furthermore, certain variables that can influence the result may have gone 
unseen. 
Hence a more representative sample of the population is needed in future studies to 
validate our findings. Hyperuricemia and gout are polygenic conditions, so other 
genes/SNPs are also involved in urate disposition. We believe that multiple genes/SNPs 
are associated with the development of HU and gout. Nevertheless, our study had a 
limited number of genes/SNPs selected from GWAS conducted in EUR.  
Other factors that may also influence urate levels, including older age, smoking, diuretic 
use, dietary and social lifestyle factors. Nonetheless, we provide primary knowledge 
that could help clinical practitioners understand the pathophysiology of diseases in some 
understudied population subgroups. Further replication in different ethnic subgroups 
with larger population samples is needed because genetic and epigenetic factors vary 
across the population, which could influence disease prevalence.  
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        Some other factors such as dietary habits, older age, and male sex contribute to HU 
and gout. Our results might partially be associated with gout pathophysiology besides 
other factors. Furthermore, study participants did not have levels of SU measured to 
conduct association analysis between genotype and phenotype. Also, in some 
subgroups, the sample size was not enough to estimate the exact prevalence of risk 
alleles, leading to a deviation from HWE.  
Conclusions 
        Our analysis suggested that HU and gout risk alleles were significantly more 
frequent in the Asian subgroup, Korean, Japanese, and Filipino, than EURs. These 
findings are consistent with previous reports suggesting that Japanese and Han-Chinese 
populations having the highest prevalence of gout/HU risk alleles than EUR. Hence, our 
findings may partially explain the three-time higher risk of gout diagnosis in Asian 
subgroups living in the US than EUR. Meanwhile, consistent with the epidemiology of 
gout, child-bearing age women are unlikely to develop gout, despite having the genetic 
risk. This the first report of its kind to investigate the genetics of uric acid in populations 
that are minimally and rarely represented in research.  
Future Perspective 
Personalized medicine based on individual genetic profiles could play a crucial role in 
predicting and addressing some health inequalities across different racial and ethnic 
groups. Our research proposes that genetic data may assess in the clinical practice by 
predicting disease risk, selecting an appropriate drug, and reducing the risk of new 
disease onset. This study is the first genetic investigation focusing on several urate 
genes/SNPs pairs and multiple underserved populations involving Asian and NHPI 
pregnant women. Furthermore, this investigation could help future research assess the 
role of HU and gout-risk-alleles in pregnant women to identify patients at higher risk of 
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maternal comorbidities such as gestation diabetes and gestation hypertension, which are 




Table 2.1: Demographic Characteristics across populations 















Mother’s age (years) 28.8±6.3 29.8±6.1 33.4±5.2 26.3±5.7 25.1±4.6 26.2±5.5 31.3±5.2 
Gestational age 
(weeks) 









Preterm (<37 weeks) 182 (17.3%) 44 (19.4%) 50 (23.8%) 27 (13.5%) 29 (18.4%) 21 (13.5%) 11 (10.8%) 
Full term (≥37 
weeks) 
871 (82.2%) 183 (80.63%) 160 (76.2%) 173 (86.5%) 129 (81.6%) 135 (86.5%) 91 (89.2%) 
Body mass index 
(kg/m2) 















63 (6.8%) 18 (9.0%) 20 (10.4%) 5 (2.9%) 10 (7.8%) - 10 (11.5%) 
Normal weight (18.5 
– 24.9 kg/m2) 
400 (43.4%) 94 (46.8%) 93 (48.4%) 44 (25.3%) 68 (53.1%) 58 (41.4%) 43 (49.4%) 
Overweight (25 – 
29.9 kg/m2) 
211 (22.9%) 56 (27.9%) 46 (24.0%) 38 (21.8%) 18 (14.1%) 30 (21.4%) 23 (26.4%) 
Obese (≥30 kg/m2) 248 (26.9%) 33 (16.4%) 33 (17.2%) 87 (50.0%) 32 (25.0%) 52 (37.1%) 11 (12.6%) 
Pre- gravida weight 
(Ibs) 










Table 2.2: Gene (SNP) and Function Summary 
Gene 
(Protein) 





Protein coding gene for ATP-binding 






Reduction in ABCG2-mediated 
urate transport by 50%, urate 
under-excretion, and 
hyperuricemia is caused by Glu 







SLC2A9 is a High-capacity urate, 
fructose, and glucose transporter 
located on both sides of the kidney's 
apical and basolateral membrane. This 
protein is expressed in liver, kidney, 
and chondrocytes tissues. Also strongly 
associated with increase serum UA. 
rs734553 (G>T) 
(Intronic variant) 
Increases risk for gout through 
altering urate transporter affinity. 







Monocarboxylic acid transporter 
protein located in the apical side of 







Reported to substantially increase 
the risk of ROL gout (p = 0.012), 








Uric acid transport protein localized at 
the apical membrane of the renal 





Known to be associated with 
decreased urate levels and the A 
allele seems to be the protective 
allele in the EUR population. 




SLC22A11 is expressed in the kidney 
and encodes the organic anion 
transporter 4 (OAT4), responsible for 
urate reabsorption regulation. 
rs17300741(A>G) 
(Intronic variant) 
It is linked to renal under-
excretion of UA in EUR descent. 







SLC22A12 is Protein encodes for urate 
transporter (URAT1), located on the 
apical side of proximal tubules and 
responsible for reabsorption of UA. 
rs505802 (C>T) 
(Intergenic variant) 
It is associated to decrease SU 
levels in the EUR population. 





Glucokinase regulator protein has a role 
in metabolic syndromes that may be 




It is associated with glucose 
metabolism, lipid regulation, SU 







Known as Scaffolding protein located 
in the apical side of the proximal tubule 
in the kidneys, which has a role in 
maintaining the balance of urate levels 




It is associated with lower serum 
urate levels among people of 





LRR16A is expressed in the apical side 
of proximal tubules in the kidneys, 
which encodes a protein called capping 
protein ARP2/3 and myosin-I linker 
(CARMIL). This protein has a role in 
urate transportome formation, which 





A risk allele related to increased 
risk of gout in Europe.  




Table 2.3: Uric acid risk allele frequencies comparisons Asian and Native Hawaiian and Pacific Islanders 






















































































55.0 (197) * 
45.0 (161) 














































































































The bolded letter refers to the risk allele linked to HU/gout  




Table 2.4: Uric acid Genotype frequencies comparisons Asian, Native Hawaiian, and Pacific Islanders 


























































































































































































































































Table 2.5: Summary of Total Risk Alleles across Asian, Native Hawaiian, and Pacific Islanders 
 
Alleles significantly different from EUR   
 
EUR Japanese Korean Filipino  Marshallese Hawaiian Samoan 
 
 














HU or/gout risk allele index*  
 
8 5 6 4 4 5 



















































































0.1473 0.1129 0.0275** 0.6046 0.0250** 0.5789 
SLC22A12 
(rs505802) 








0.8788 0.9410 0.8211 0.0000 0.4077 0.8743 
LRRC16A 
(rs742132) 
0.8602 0.3476 0.4492 0.1642 0.0384** 0.8089 
GCKR 
(rs780094) 
0.3981 0.4903 0.9620 0.9112 0.3209 0.4184 























Filipino  96.3 92.1 94.2 94.2 91.5 88.9 92.6 94.7 94.7 
Japanese 98.4 97.3 96.8 98.9  95.2 96.2 97.8 98.4 98.4 
Korean 97.9  93.6 95.9 96.8 95.7 85.2 97.8 95.7 96.8 
Native 
Hawaiian 
99.3 98.6 98..6 99.3 95.2 92.4 97.9 98.6 98.6 
Marshallese 93.8 91.4 92.2 94.6 93 88.3 93.7 93 93.7 
Samoans  98.4 96.7 97.3 97.3 97.3 91.4 97.3 97.3 97.8 




Table 2.8: Abbreviations 
SU Serum urate 
HU Hyperuricemia 
SNP Single nucleotide polymorphism 
NHANES National Health and Nutrition Examination Survey 
GWAS Genome-Wide Association Studies 
EUR European 
NHPI Native Hawaiian and Pacific Islander 
HD Health Disparities 
CVD Cardiovascular Disease 
IR Insulin Resistance 
CKD Chronic Kidney Disease 
PE Preeclampsia 
MAF Minor Allele Frequency 
HWE Hardy-Weinberg Equilibrium 
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Chapter 3: Assessment of Cardiometabolic Risk Factors among selected Pregnant 




Preeclampsia (PE), known as severe new onset of the hypertensive disorder 
occurring after 20 weeks of gestation, can lead to maternal and fetal defects. Several 
risk factors are associated with developing PE. The most common risk factors include 
the history of comorbid conditions, advanced/younger age, high body mass index 
(BMI), or history of chronic kidney disease (CKD). Hyperuricemia (HU) was found to 
be an independent risk factor for developing cardiovascular diseases. Biologically, 
dysfunctional urate transporters due to genetic polymorphisms could lead to clinical 
consequences associated with increased or decreased serum urate (SU) levels. HU has 
been reported as a significant risk predictor of developing cardiometabolic diseases 
(CMDs). Examples of CMDs include chronic hypertension (CHTN), gestational 
hypertension (GHTN), diabetes mellitus (DM), and gestational diabetes mellitus 
(GDM). CMDs are considered major risk factors associated with developing PE. 
Therefore, this study focuses on assessing the genetics of uric acid disposition and other 
non-genetic factors in developing CMDs across selected pregnant Asian-Pacific 
Islander groups. 
Methods 
The biospecimens repository at the University of Hawaii provided DNA samples 
of consenting post-partum women. The DNA was extracted from the cord blood and 
genotyped at the Genomics and Bioinformatics Shared Resource, Cancer (Honolulu, 
HI). Nine urate genes—ABCG2, SLC2A9, SLC16A9, GCKR, SLC22A11, SLC22A12, 
LRR16A, PDZK1, and SLC17A1—were selected due to their significant association with 
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HU and gout risk. Age and BMI were selected as non-genetic risk factors associated 
with developing CMDs.  
The Hardy-Weinberg Equilibrium (HWE) for genotype frequencies was 
assessed using the Chi-Square test with p<0.05 for statistical significance.  
The association between genotype and CMDs phenotypes (CHTN, GHTN, DM, and 
GDM) were assessed using chi-square or Fisher exact test as appropriate at p<0.05 in 
different genetic assumption models (Additive, Dominant, and Recessive). Then a 
logistic regression analysis test was used after conducting a global hypothesis test to 
determine the association between age, BMI, and CMDs phenotype. Finally, the 
univariate statistical analysis (ANOVA) was used to ascertain the association between 
BMI and different UA genotypes. 
Results   
This study involved 429 post-partum pregnant women aged 18 years or older 
who self-reported their respective race and ethnicity. Specifically, we chose the Filipino 
group as the Asian subgroup and the Samoan population as the Pacific Islander 
subgroup. No one of the participants reported a history of gout disease. Based on the 
HWE results, we excluded some UA gene/SNPs in Filipino and Samoan sample 
populations. All UA risk alleles were consistent with HWE (p>0.05), except PDZK1 
(rs12129861 C>T) in both groups, and SLC16A9 (rs2242206 G>T) in the Samoan group 
(p =0.0275). Using a chi-square test, we found a significant association between UA 
genotype and diabetes mellitus in the Filipino group. These genotypes were ABCG2 
(rs2231142 G>T) in both additive and recessive models 75% vs. 18.9% (p=0.016, 
0.026, respectively).  
Meanwhile, in the Samoan group, we found trending toward significant 
differences between the recessive genetic model of UA genotype of SLC22A11 
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(rs17300741 A>G) in the CHTN and GDM. The proportion of UA AA genotypes 
trended significantly higher in the presence of CHTN (100%) versus (61.2%) in 
participants without (p=0.085). The proportion of the UA genotype AA of SLC22A11 in 
the presence of GDM was trending toward a significantly higher, around (80.9%) vs. 
(60.2%) in the Samoan population without GDM (p=0. 063). In performing a logistic 
regression analysis, we found age associated with developing CHTN (OR=1.11, 1.026-
1.225 95% CI, p=0.0139) in the Filipino population. Moreover, we found a trending 
toward a significant association between BMI and CHTN in the Filipino cohort 
(OR=1.08, 0.99- 1.13 95% CI, p= 0.06). Furthermore, age also associated with 
developing GDM in the Samoan population (OR=1.15, 1.063- 1.254 95% CI, p= 
0.0006).  
In a univariate analysis test in the Filipino sample population, our results found a 
significant difference in the mean BMI among ABCG2 (rs2231142 G>T) within the 
dominant model (mean of GT+ TT= 24.14 relative to GG (reference)= 26.88, (p= 0.04). 
In the Samoan population, we found a trending toward significant under the additive 
model of GCKR (rs780094 C>T) (mean of TT= 26.56 compared to 29.72 of CC 
(reference), (p = 0.08). Moreover, significant differences in mean BMI have been 
shown in the Samoan population under the additive and recessive model 
of LRRC16A (rs742132 A>G). Under the additive model, the mean BMI of AA 
(genotype risk) was lower, 27.47 relative to 28.65 of GG (reference) p=0.03. Moreover, 
under the recessive model, the mean BMI of AA (genotype risk) was lower, 27.47 
compared to 30.3 of AG+GG (reference) p=0.031). 
Conclusion 
The UA risk alleles were associated with the development of diabetes mellitus 
among the Filipino group. In contrast, they were trending toward an association 
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between UA risk alleles and gestational diabetes and chronic hypertension in Samoan 
ancestry. Age risk factors have shown an association with CMDs developments in both 
Filipinos and Samoans. Moreover, BMI has shown an association with CHTN in the 
Filipino population. Our statistical analysis results are consistent with a previous study 
that confirms the Asian population had the highest prevalence of UA risk alleles relative 
to the Pacific Islander population. In addition, these results are consistent with current 
studies showing that the Asian population has the highest prevalence of CMDs 
compared to the Pacific Islander population. 
Key Words: Asian-Pacific Islanders, Gestational Diabetes, Chronic Hypertension, 




Preeclampsia (PE) is a new onset of the hypertensive disorder occurring after 20 weeks 
of gestation, potentially leading to maternal and fetal defects. This condition affects up 
to 8% of pregnant women in the world. Additionally, in the US, severe PE risk 
increased up to six-fold between 1980 and 2003, which increased the burden and costs 
on the health care system.165 Several risk factors are related to developing PE, including 
family history, multiple pregnancies, maternal comorbidities such as diabetes, CVD, 
CKD, genetic predisposition, and in some population such as African and African-
American ancestry (odds ratio [OR]: 3.70, 95% CI: 2.19–6.24) compared to white 
women.166–168 Nakagawa et al. found the prevalence of PE in the under-represented 
population of Hawaii to be higher among the Asian and Pacific Islander populations.169 
Several studies have suggested the association between UA during pregnancy and PE 
causing severe maternal and fetus complications.170  
        Chemically, uric acid (UA) is the final product of purine metabolism.171 Placental 
ischemia enhances xanthine oxidase (XO) activation, further activating uric acid 
formation.172 The first discovered association between high serum uric acid (SU) and 
PE in pregnant women was in 1934.173 In 2008, a large-scale prospective multi-center 
study was conducted by Paula et al., wherein it was pointed out that SU level correlated 
with the perinatal prognosis of patients with hypertensive disorders of pregnancy 
(HDP).174  
Hyperuricemia (HU) potentiates PE by stimulating inflammation, endothelial 
dysfunction, and oxidative stress.175 Multiple studies reported the association between 
SU and adverse maternal outcomes. Maternal gout, for instance, was found to be 
associated with an increased risk of low birth weight, preterm birth, Cesarean delivery, 
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and PE pathology.176,177 A recent study reported a correlation between hypertension and 
UA levels, as well as the predictive capability of UA levels in severe PE.178 
Additionally, some studies suggest that HU could be an essential indicator for 
pregnancy-related disorders, including HDP development, PE, and preterm birth.177 
Hyperuricemia could lead to hypertension and proteinuria, which are clinical markers 
commonly used to diagnose PE.179 Women with PE have elevated SU, representing an 
equally effective marker to proteinuria in detecting perinatal risk in gestational 
hypertensive women.180’181 Relative to women with PE and normal SU, women with PE 
and hyperuricemia have a higher risk of adverse perinatal outcomes.180,181 Nonetheless, 
a correlation between hyperuricemia and maternal and fetal morbidity pointing to its 
diagnostic value in predicting PE development has been reported.182 
Hyperuricemia could be utilized as a predictor of fetal outcome in women with 
PE. Studies have found that women with hyperuricemia occurring before 35 weeks of 
gestation often have deliveries with adverse consequences, such as intrauterine growth 
restriction (IUGR) and intrauterine death (IUD).183 A recent study reported that 72% of 
newborns of mothers with hyperuricemia had low birth weights. In comparison, 62% of 
newborns from women with normal uric acid levels had average birth weights.184   
Despite these promising findings, it is unclear whether UA could be used as a 
marker for PE or adverse maternal outcomes.182 Opposing studies have suggested that 
high SU was not related to negative maternal effects. Moreover, SU may not be 
involved in PE development, and thereby might not be a reliable marker for predicting 
the incidence of adverse pregnancy outcomes.185 Studies investigating the effects of SU 
on pregnancy and its potential as a marker for various maternal outcomes were 
inconsistent.    
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HU has the potential to inhibit trophoblast invasion of the placenta, resulting in 
reduced blood supply and oxygen for the fetus.186 Biologically, HU could also reduce 
nitric oxide (NO) production in endothelial cells, contributing to poor trophoblast 
invasion187. This mechanism could imply the role of HU in PE pathogenesis.175 
PE can happen due to several risk factors involving coexisting comorbidities, 
most of which could be associated with HU/gout. Furthermore, several risk factors may 
increase the risk of PE, such as diet and social factors, socioeconomic status, and 
psychological disorders. Additionally, some ethnic groups—for instance, African 
Americans—have a significantly higher risk of PE.188,189  
Genetic polymorphism of the urate transportome may lead to clinical disorders 
such as hyperuricemia. An example of the UA genes is SLC22A12 (URAT1), ABCG2, 
which showed a strong association with chronic renal injury. 190’139 Interestingly, 
reports showed significant association between various UA risk alleles, single 
nucleotide polymorphisms (SNPs), and PE among pregnant South African women. A 
case-control study demonstrated a strong association between the human urate 
transporter  SCL22A12/ rs502802 (URAT 1) and PE, specifically late-onset PE versus a 
control group of pregnant women (OR=1.73, 95% CI=1.258- 2.442, p=0.028).191   
The results of that previous study may highlight a possible role of UA risk 
alleles in the development of chronic metabolic diseases. The link between HU/gout and 
chronic complications, such as cardiovascular diseases (CVD), renal impairment, and 
metabolic syndromes, may be exacerbated by HU. HU is implicated in the progress of 
many metabolic diseases, as previously mentioned.192 Clinically, several risk factors 
have been associated with the development of PE disease. According to the National 
Institute for Health and Care Excellence (NICE) guidelines, these risk factors are 
classified into high and moderate levels. If the pregnant women had a history of 
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hypertension in their last pregnancy or suffered from gestational diabetes, kidney 
disorders, or autoimmune diseases, they were classified at a high risk of PE. 
Additionally, some other clinical factors like the woman’s age (≥ 40-years) or body 
mass index (BMI) ≥ 35 kg/m2, as well as other risks, were classified as moderate 
clinical determinants.193 Pregnant women diagnosed with diabetes mellitus as well as 
those who develop gestational diabetes are at a two- to four-fold risk of being diagnosed 
with preeclampsia.194  
In this study, we hypothesized that UA genetic polymorphisms and non-genetic 
factors including age and BMI may contribute to metabolic disorder development, 
which are major risk factors for maternal outcomes in the Asian and Pacific Islander 
subgroups. This study proposed to look at the impact of several UA gene/SNP pair 
variations among selected pregnant women, variations that had been shown to cause 
cardiometabolic syndromes such as diabetes mellitus (DM), gestational diabetes 
mellitus (GDM), chronic hypertension (HTN), and gestational hypertension (GHTN). 
Finally, this analysis aimed to assess the association between genetic/non-genetic risk 
factors contributing to cardiometabolic disorders, which a major risk factors of PE 
disease. 
 Methods 
Preliminary Statistical analysis 
Previously, we aimed to test an association between cardiometabolic diseases 
and UA risk alleles using simple and multiple logistic regression analysis, adjusting for 
other covariates, including age and body mass index (BMI), across the entire sample 
population of the Asian and native Hawaiian-Pacific Islander populations. 
Unfortunately, the results were uninterpretable because they were biologically and 
directionally inconsistent with some UA genes associated with cardiometabolic 
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diseases. We postulated that inconsistency might partly be due to the low frequency of 
the outcomes and population heterogeneity. All previous statistical analyses appear 
in the appendix section.  
As a follow-up, we decided to focus our analysis only on Filipino and Samoan 
groups using logistic regression analysis. Although the logistic regression results were 
uninterpretable with some genes, it pointed to the possibility of specific non-genetic risk 
factors associated with developing CMDs. We describe the process in the appendix 
section. 
Frist, we used chi-square and Fisher exact tests at p<0.05 to compare the 
prevalence of comorbidities in the Asian population versus native Hawaiians and 
Pacific Islanders. We summarize all the results in Table 3.3. Figure 3.1 
In addition, we compared the same comorbidities conditions among Filipino relative to 
the Samoan population, as well we compare the prevalence of each ethnicity to the 
overall population. We summarized all findings in the Table 3.2., Figure 3.2. 
To minimize the heterogeneity within the population, while considering the sample size 
and the frequency of the outcome of interest, we decided to focus our analysis only on 
Filipino and Samoan populations to run genetic and non-genetic factors models. We 
assessed the association between CMDs and the prevalence of HU genotypes, using chi-
square or Fisher exact test p<0.05. In addition, we used multiple logistic regression 
models to test the association between non-genetic risk factors (age/BMI) and 
cardiometabolic diseases. Moreover, a univariate analysis test (ANOVA) was used to 
analyze the differences among mean BMI between different genotypes of UA genes. 
We reported the results of the exploratory analysis of the entire cohort combined in the 
appendix section. 
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Study participant and urate genes 
Participants in this study were pregnant women ≥18 years old. All of them self-
reported as having Asian or Pacific Islander subgroups ancestry (Filipino and Samoan). 
Age, gestational age, BMI, and other demographic information were provided. In Table 
3.1, we summarize all demographic characteristics. Blood samples were collected from 
participants for DNA extraction. The uric acid genes addressed in this study include 
SLC17A1 (rs1183201), PDZK1 (rs12129861), SLC22A11 (rs17300741), ABCG2 
(rs231142), SLC2A9 (rs734553) G>T, SLC164A9 rs2242206, SLC22A12 (rs505802), 
CARMIL1, LRRC16A rs742132, and GCKR (rs780094). It should be noted that the 
University of Hawaii provided all data we mentioned.  
Following HWE analysis results and other quality assessments across the 
selected population groups, we excluded PDZK1, SLC2A9 in both groups, and 
SLC16A9 genes in the Samoan population. Social risk factors such as a history of 
smoking and alcohol use were reported in the demographic information (Table 3.2). 
Maternal medical conditions, including gestational hypertension, chronic hypertension, 
gestational diabetes, diabetic mellitus, Preeclampsia, and premature labor, were also 
reported and appear in Table 3.2. Participants’ younger than18 years of age or having a 
history of cancer and/or organ transplants were excluded.   
Sample procurement and genotyping 
Genotype, medical, and demographical information were provided by the University of 
Hawaii biospecimens repository. Post-partum women gave consent to donate their 
placentas and umbilical cords. The DNA was extracted from the blood and genotyped at 
the genomics and Bioinformatics Shared Resource, Cancer center (Honolulu, HI). A 
customized TaqMan genotyping assay panel was run on the Quant Studio 12K Flex 
Real-Time PCR system (Applied Bio systems). All study details were previously 
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published.129 All study materials were reviewed and exempted by the University of 
Hawaii Human Studies Program (protocol Number: 2018-00225). 
 
Statistical analysis 
Data obtained during the study were analyzed utilizing R software Version 
1.3.1073. We assessed our data with Hardy-Weinberg Equilibrium at P <0.05 across our 
selected population (Table 3.6). Chi-square statistical analysis and Fisher exact tests 
were used to estimate the associations between gene variations and cardiometabolic 
phenotypes across all three genetic models (additive, dominant, and recessive) at 
p<0.05. The phenotypes of interest were presence and absence of gestational 
hypertension, gestational diabetes, chronic hypertension, and diabetic mellitus. Other 
risk factors, including age and BMI, were assessed in relationship to cardiometabolic 
diseases using multiple logistic regression analysis tests and reported odds ratios (OR), 
95% CI and p-value <0.05 for statistical significance. The association of BMI amongst 
the different genotypes of UA genes was determined using one-way ANOVA. 
Results 
Our previous study concluded that the Asian population had the highest 
prevalence of UA risk alleles as compared to native Hawaiians and Pacific Islanders 
(Table 2.5). Moreover, our results show that the Asian population had a significantly 
higher prevalence of cardiometabolic disorders as compared to native Hawaiian and 
Pacific Islanders (Table 3.3) (Figure 3.1). Consistently, the current study has shown that 
Filipinos have the highest prevalence of cardiometabolic diseases relative to the 
Samoans (Table 3.2, Figure 3.2). The demographic, clinical, and social characteristics 
across selected population ancestry is summarized in Table 3.1.  Among all uric acid 
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gene/SNPs, some deviated from HWE, and those deviations are summarized in Table 
3.6.  
Hardy-Weinberg Equilibrium and quality control  
We used a chi-square statistical test analysis to perform HWE principle in order to 
check all genes/ SNPs for deviation or consistency in regard to HWE across selected 
populations. In both Filipino and Samoan populations, all UA risk alleles were 
consistent with HWE, except PDZK1 (rs12129861 C>T) in both subgroups, and 
SLC16A9 (rs2242206 G>T) in the Samoan population p =0.0275 (Table 3.6). In 
addition, we excluded SLC2A9 (rs734553 G>T) in both groups due to a lack of GG 
frequency.  
 
Association of UA Genotypes (Additive, Dominant, and Recessive models) and 
Cardiometabolic Diseases amongst Filipino and Samoan Subgroups  
Based on the overall dataset, the prevalence of comorbid diseases, and the 
largest sample size across Asian, native Hawaiians, and Pacific Islanders, we selected 
the Filipino and Samoan population groups to determine the association between 
genotypes and phenotypes. All UA genotype risk alleles were included in the Filipino 
population except PDZK1, due to its deviation from HWE (Table 3.6). In the Samoan 
population, we excluded PDZK1 and SLC16A9 out of a total of nine UA genes, also due 
to their deviation from HWE (Table 3.6).  
In the Filipino cohort, we found a trending toward significant differences 
between SLC16A9 (rs2242206 G>T) and CHTN. The proportion of the TT risk allele of 
SLC16A (rs2242206 G>T) was lower (0%) in the presence of CHTN, relative to 
(24.4%) in participants without CHTN in both additive (TT vs. GT vs. GG (reference)) 
and recessive (TT vs. GT+TT (reference)) models (p=0.09, 0.07), respectively. 
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Moreover, our analysis has not shown any statistical significance among the rest of UA 
genes and chronic hypertension in Filipinos (Table 3.5). Meanwhile, in the Samoan 
group, there was trending toward a significant relationship between SLC22A11 
(rs17300741 A>G) and CHTN. Under the recessive model (AA vs. AG+GG 
(reference)), the proportion of AA risk alleles were higher (100%) in participants who 
were diagnosed with CHTN compared to (61.2%) in participants without. (p=0.08). 
(Table 3.4). 
Across the Filipino population, for those with diabetes mellitus (DM), there was 
a significantly higher prevalence of genotype risk alleles of ABCG2 (rs2231142 G>T) 
and diabetes mellitus in both additive and recessive genetic models. (Table 3.5). The 
proportion of TT risk allele of ABCG2 (rs2231142 G>T) in the additive model (TT vs. 
GT vs. GG (reference)) and recessive model (TT vs. GT+TT (reference)) was 
significantly higher in the presence of DM (75%) as compared to the absence of DM 
(18.9%) (P=0.016, 0.026), respectively. (Table 3.5).  
In contrast, within the Samoan group, our analysis found a significantly lower 
proportion of TT risk genotype of SLC17A1 (rs1183201 T>A) in the presence of DM 
than in its absence (p<0.05) (Table 3.4). Our statistical analysis results have not shown 
any significant differences between UA genotypes and gestational hypertension 
phenotype in both Filipino and Samoan groups (Table 3.4 & Table 3.5).  
In gestational diabetes mellitus (GDM), our analysis did not show any statistical 
differences in the proportion of UA genotype and phenotype across the Filipino 
population. However, in the Samoan population, we saw a trending toward a significant 
association between SLC22A11 (rs17300741 A>G) and GDM. Under the recessive 
model (AA vs. AG+GG (reference)) of SLC22A11 (rs17300741 A>G), the proportion of 
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AA genotype was higher (80.9%) in participants who had been diagnosed with GDM 
compared to (60.2%) in Samoan participants without (p=0.06). (Table 3.4).  
Association of Cardiometabolic Diseases (CHTN, DM, GHTN, and GDM) and non-
genetic risk factors (BMI and age) amongst Filipino and Samoan population 
We used multiple logistic regression analysis models for both global and 
secondary hypothesis to estimate age and BMI, which are considered non-genetic risk 
factors associated with the development of cardiometabolic diseases. We found what we 
determined to be an odd ratio, 95% CI, and p-value of multiple logistic regression 
analysis, which has been summarized in Table 3.7. 
Results of the analysis show higher odds significantly associated between 
CHTN and age in the Filipino subgroup [(OR=1.11, 95% CI= 1.026- 1.225, 
p= 0.0139)], as well as a trending toward significant in BMI [(OR=1.06, 95% CI= 
0.991- 1.135, p= 0.06)] (Table 3.7).  No significant association was found to exist 
between age, BMI, and diseases such as DM, GDM, and GHTN in the Filipino 
population. (Table 3.7). In contrast, for the Samoan population, the statistical analysis 
showed a significant association between age and GDM [(OR=1.15, 95% CI= 1.06- 
1.25, p= 0.0006)]. (Table 3.7). 
The differences in the mean BMI amongst UA genotypes in Filipino and Samoan 
population 
In this part of the analysis, we tested the differences in the mean BMI across the 
different genotypes of UA genes in all three genetic models (additive, dominant, and 
recessive). I started to test the assumption of variance using Bartlett’s test to decide on 
using equal/unequal ANOVA. The statistical analysis showed a significant difference in 
the mean BMI of ABCG2 (rs2231142 G>T) under the dominant model (GT+TT vs. GG 
(reference)) across the Filipino population. Thus, the mean BMI of GT+TT of the 
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dominant model was lower relative to the mean of the GG (reference) genotype (mean= 
24.14 vs. 26.88, p=0.04), respectively. (Table 3.8) (Figure 3.3)  
However, in the Samoan subpopulation, a trending toward significant was found 
between mean of BMI and TT genotype of the additive model (TT compared to CC) 
of GCKR (rs780094 C>T) (mean BMI of TT genotype was 26.56 relative 29.72 of CC 
(reference) genotype (p=0.08). (Table 3.9) (Figure 3.4). Moreover, in the Samoan 
population, significantly lower differences were found under additive (GG (reference) 
vs. AG+GG) and recessive (AG+GG (reference) vs. AA) genetic models of LRRC16A 
(rs742132 A>G). The mean BMI of AA was 27.47 is in contrast to the reference GG= 
28.65, (p=0.03) in the additive model (Figure 3.5), while in the recessive genetic model, 
the mean BMI of AA= 27.47 was lower than the reference AG+GG= 30.31 at (p=0.03) 
(Figure 3.6). Furthermore, no significant differences were found in the remaining genes 
and BMI across both populations (Table 3.9). 
Discussion 
        Hypertension is considered one of the most common diseases in the Asian/Pacific 
Islander populations.195 Pregnant women with a history of CHTN are considered more 
susceptible to a higher risk of PE.193 Among many risk factors, UA is associated with 
the development of cardiovascular diseases. Genetic polymorphisms of urate 
transporters could cause an imbalance between urate excretion and reabsorption, which 
could lead to metabolic disorders. Therefore, a high UA level could be an independent 
predictor of several complications, such as hypertension.22 In our Filipino cohort, the 
proportion of most UA genotypes were higher in participants that had CHTN versus 
participants without CHTN, but there was not enough evidence to suggest a statistically 
significant association (P>0.05). (Table 3.5). An example of UA risk alleles associated 
with CVD is GCKR (rs780094 C>T) gene polymorphism, which is related to 
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triglyceride and other cardiovascular risks.196 Our data analysis shows an insignificantly 
higher proportion of T risk allele of the GCKR (rs780094 C>T) in the presence of 
CHTN in all three genetic models (additive, dominant, and recessive) (36.4% vs. 
20.7%, and 72.8% vs 67.4% vs. 36.4, and 20.7%, respectively, (p>0.05) (Table 3.5). At 
this point, our results are inconsistent with available literature; therefore, further studies 
should be conducted on a large enough sample size in order to validate the existing 
results.   
On the other hand, in the same Filipino group, the proportion of T risk allele 
of SLC16A9 (rs2242206 G>T) trended significantly lower in women who had CHTN 
compared to those without CHTN (0% vs. 24.4% p=0.090 in additive model (GT+TT 
vs. GG (reference) and 0% vs. 24.4% p=0.069 in the recessive model (TT vs. GT+GG 
(reference)) (Table 3.5). The results we found conflict with the physiological function 
of SLC16A9 and its metabolic trait association. SLC16A9 codes for a monocarboxylic 
acid protein (MCT9), which has a role in carnitine transportation and UA excretion 
from the intestine. Carnitine is mostly excreted through the glomerular tubules of the 
kidney. Based on kidney function, carnitine is a competitive substrate in regard to UA. 
If it is not excreted well, carnitine could cause renal overload gout due to high UA, 
causing cardiovascular dysfunctions and other metabolic traits.197 
By contrast, in the Samoan subgroup, the study analysis results show a trend toward a 
significantly higher proportion of AA genotype of SLC22A11 (rs17300741 A>G) under 
a recessive genetic model (AG+GG (reference) vs. AA) in regard to the presence of 
CHTN relative to non-CHTN. The proportion of AA genotype (100%) relative to 
AG+GG (61.2%) p=0.0851). (Table 3.4). Flynn et al. have found that the SLC22A11 
(OAT4) is strongly associated with UA and gout in the Pacific Islander population.198 
Apart from this, we found that in our cohort, the prevalence of the A risk allele is 
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significantly higher in both the Asian and native Hawaiian and Pacific Islander 
populations than EUR.  
Additionally, ABCG2 (rs2231142G>T), LRRC16A (rs742132 A>G), and GCKR 
(rs780094 C>T) genotypes were insignificantly associated with increased risk of CHTN 
in the Samoan population. Conversely, SLC22A12 (rs505802 C>T) and SLC17A1 
(rs1183201 T>A) UA risk alleles were insignificantly lower in CHTN risk development 
p >0.05 across the Samoan population. (Table 3.4). 
Gestational hypertension (GHTN) can occur during pregnancy, causing an 
elevation in blood pressure. During the first quarter of pregnancy, if the UA levels are 
about 3.15 mg/dl it can be indicative of GHTN, which is classified as a decisive risk 
factor of PE development. Hence, UA level is one of the predictive factors for 
cardiometabolic diseases.199 Our analysis showed that Filipino-American population 
groups in Hawaii had an insignificant association between UA gene polymorphisms and 
GHTN. In the Filipino subgroup, UA genotypes of SLC22A11 (rs17300741 A>G), 
SLC17A1 (rs1183201 T>A), ABCG2 (rs2231142 G>T), SLC16A9 (rs2242206 G>T), 
and LRRC16A (rs742132 A>G) were insignificantly higher in the proportion of the risk 
allele in the presence of GHTN (Table 3.4). It should be noted that Filipino-Americans 
tend to have a higher risk of developing cardiometabolic conditions due to numerous 
risk factors.200  Further studies are needed to explore the role of genetic factors 
associated with heart-related diseases in the Filipino-American group. 
On the other hand, our results have not shown any significant association 
between UA gene polymorphisms and GHTN development in the Samoan subgroup. 
Most UA genotypes had an insignificantly higher proportion in the presence of GHTN 
relative to absence status p>0.05 in the Samoan population. These alleles include 
SLC22A12 (rs505802 C>T), SLC17A1 (rs1183201 T>A), SLC22A11 (rs17300741 
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A>G), and GCKR (rs780094 C>T) in all three genetic models, while ABCG2 
(rs2231142 G>T) only appeared in dominant genetic model (Table 3.4). Although our 
results may not be statistically significant, they are consistent with the biological 
function of the association between UA gene polymorphisms and CMDs 
development.197  The T risk allele of GCKR (rs780094 C>T) is an example of a 
polymorphism that is biologically associated with the cardiometabolic trait.201  
However, the AA genotype of LRRC16A (rs742132 A>G) was insignificantly lower in 
proportion in regard to the presence of GHTN as compared to Samoan pregnant women 
without GHTN in both dominant and recessive models p>0.05 (Table 3.4). What’s 
more, LRRC16A genes have a biological role in metabolic traits, and our cohort results 
show the opposite physiological direction in the Samoan population. We can hence 
conclude that not only genetic factors contribute to metabolic diseases across the 
different populations; indeed, there may be many other factors. This explanation leads 
us to focus on other risk factors such as BMI and study their relationship to metabolic 
traits. Lee et al. have reported that BMI over 21 kg/m2 and obesity are associated with 
coronary heart disease at a level of approximately 58% in Samoan-Americans.202 
Conversely, In the Filipino cohort, our analysis showed that the prevalence of AA 
genotype of LRRC16A (rs742132 A>G) was higher in proportion in the presence of 
GHTN relative to pregnant women without GHTN, but there was no evidence to fully 
support that association (P>0.05) (Table 3.5). 
Diabetes mellitus (DM) is a metabolic disorder resulting in reduced insulin 
secretion, causing an elevation of the blood glucose level, leading to hyperglycemia.203 
A history of DM, either type 1 or 2, among pregnant women increases the risk of PE as 
well as gestational diabetes.194 Biologically, there is a potential association between 
urate transporters’ heritability and metabolic disorder development.197 Hence, we 
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conducted our analysis toward detecting an association between diabetes, gestational 
diabetes, and UA genetic polymorphisms across Filipino and Samoan subgroups. 
SLC22A12 (rs505802 C>T) is encoded for urate transporter 1 (URAT1), a major 
transporter responsible for urate reabsorption. In addition, SLC22A12 has a role in 
phosphorylation enzyme called phosphokinase-c (PKC), which contributes to activating 
phosphoinositide inositol-3 kinase (PI3K), which is associated with insulin secretion 
and glucose uptake. Reduced function in this protein reduces insulin secretion from the 
beta cell, causing insulin resistance and DM. 197 Although the prevalence of the CC 
genotype of SLC22A12 (rs505802 C>T) has been shown to be higher in the presence of 
DM than in non-DM Filipino pregnant women in an additive model (TT (reference) vs. 
CC)) 75% vs. 60.9%, respectively, our analysis did not show any significant association 
(p=0.10) (Table 3.5). In addition, another genetic model had also found a non-
significantly higher proportion of the C risk allele SLC22A12 (rs505802 C>T) in 
participants with DM as compared to the non-DM p>0.05 across the Filipino cohort 
(Table 3.5).   
In the same Filipino cohort, the proportion of TT genotype of ABCG2 
(rs2231142 G>T) shows a significantly higher association that contributed to DM 
relative to women without DM in both additive and recessive genetic models (75% vs. 
18.9% p 0.01627 and 75% vs. 18.9 p= 0.02611, respectively) (Table 3.5). It is well 
established that ABCG2 is highly associated with hyperuricemia and gout across 
different populations, and that it possibly contributes to cardiometabolic illnesses such 
as diabetic mellitus.204  
As previously mentioned, SLC16A9 codes for a protein monocarboxylic acid 
transporter 9 (MCT9), which has a role in carnitine transporter that assists in insulin 
secretion improvement; thus, lack of SLC16A9 function is associated with many 
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conditions such as type 2 DM and cardiovascular disorders.197  Our analysis has found a 
non-significantly higher proportion of the TT genotype of SLC16A9 (rs2242206 G>T) 
under a dominant model (GT+TT vs. GG (reference)) across Filipino participants that 
had DM relative to participants without (75% vs.66.8%, respectively, p=1). Other 
genetic models also resulted in higher proportions but were not considered statistically 
significant (Table 3.5). Furthermore, the analysis has found a higher proportion in both 
genotypes of SLC22A11 (rs17300741 A>G) and GCKR (rs780094 C>T) in regard to 
those with DM within the Filipino cohort, but these proportions were statistically 
insignificant (p>0.05) (Table 3.5). Our final analysis showed an association between 
UA genotypes and developing DM across Filipino pregnant women, supporting that 
hyperuricemia may be considered a predictor of the risk factor for CMD.  
        In the Samoan subgroup, our analysis found a non-significantly higher proportion 
of the AA risk genotype of SLC22A11 (rs17300741 A>G) across pregnant women who 
had DM (75%) as compared to those without DM (62.3%), P>0.05. The remainder of 
the genes—including SLC22A12 (rs505802 C>T), ABCG2 (rs2231142 G>T), SLC16A9 
(rs2242206 G>T), LRRC16A (rs742132 A>G), GCKR (rs780094 C>T)—have zero 
prevalence of UA risk genotypes, which has an effect on the results (Table 3.4). These 
results lead us to look for other risk factors related to DM, such as obesity and age of 
the pregnant woman, as well as other demographic characteristics.  
       Gestational diabetes mellitus (GDM) is a subtype of DM, and it occurs most often 
in the mid-phase of pregnancy. Relating to PE, GDM increases the risk of PE by about 
30%; it can also have negative effects on both the mother and her fetus.205 The analysis 
shows trending toward a significant association between the AA genotype 
of SLC22A11 (rs17300741 A>G) and GDM across the Samoan population. Under the 
recessive model (AG+GG (reference) vs. AA), the proportion of AA was higher 
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(80.9%) of the pregnant Samoan with GDM compared to (60.2%) in those without 
GDM (p=0.06) (Table 3.4). This indicates that the prevalence of GDM amongst the 
Pacific Islander population was very high, particularly in the Samoan subgroup.206  
In both subgroups, our results did not find any significant association between 
remaining UA SNPs risk alleles and GDM (p>0.05) (Table 3.4 & Table 3.5). In fact, 
along with UA genetic risk factors, GDM might occur through different causes, and 
maternal obesity is considered a major one of those causes.207 
In summary, this cohort analysis aimed to detect a genetic association between 
UA genotypes and CMDs among the Asian/Pacific Islander population, specifically 
those in the Filipino and Samoan subgroups. Genetically, the Samoan population is at 
risk of developing CHTN and GDM due to UA risk alleles of SLC22A11. Meanwhile, 
the Filipino subgroup has shown a high risk of CMDs, mainly DM, due to genetic 
polymorphism in ABCG2. Overall, from a genetic perspective of urate heritability, we 
would argue that both Filipino and Samoan populations are at a higher risk of 
developing cardiometabolic disorders. These findings are partially consistent with our 
previous results that found Asian subgroups and the Filipino population to have the 
highest prevalence of UA risk alleles and cardiometabolic disorders relative to the 
population cohort and its subgroups of native Hawaiian and Pacific Islanders (Table 
2.5& Table 3.4). 
Non-genetic risk factors (Age, BMI) and development of comorbid Diseases (CMDs) 
The logistic regression analysis test was used amongst Filipino and Samoan 
subgroups to determine nongenetic risk factors involving the mother age and BMI 
associated with CMDs progression. All associations between nongenetic risk factors 
and CMDs were summarized in the Table 3.7. Across the Asian-Pacific community, 
obesity is associated with an increased risk of comorbid diseases.208 Along with the 
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relationship between CMDs and PE, obesity and advanced maternal age could be 
classified as moderate risk factors associated with PE.193 
Our analysis has shown an association between age and CHTN in Filipino 
pregnant women (OR = 1.11, 95% CI = 1.026- 1.225, p = 0.0139 *). In addition, BMI 
has been shown to be associated with CHTN in the Filipino population (OR=1.06, 95% 
CI= 0.99-1.13, p=0.06). (Table 3.7). This result is consistent with other data published 
in 2018 that reported that those Filipinos of an older age and those with a BMI greater 
than 23kg/m2 were considered to be at risk for developing hypertension.209  
Whereas Linhart et al. have reported that obesity and an increased BMI rate are 
strongly associated with hypertension across the Samoan population210, the global 
hypothesis test results of age/BMI covariates related to CHTN was insignificant 
(p>0.05), which did not show an association between BMI and GHTN in the Samoan 
population  (Table 3.7).  
Sugiyama et al. have reported  that Pacific Islander pregnant women who are 30 
years or older and have a BMI ≥ 30 kg/m2 are at a higher risk of GDM and maternal 
consequences such as high weight infants and fetal death as compared to women 
without GDM.211 Moreover, the severity of perinatal outcomes due to GDM vary across 
ethnicities. The multiple logistic results show that age is considered a significant high-
risk factor for development of GDM in the Samoan population (OR= 1.15, 95% CI = 
1.06- 1.25, p = 0.0006 ***). Although the odds of BMI were positive in GDM in the 
Samoan cohort, there was no evidence to suggest that association p>0.05 (Table 3.7). 
This analysis shows that age and BMI could be contribute to cardiometabolic disorders, 
which may negatively impact both mothers and fetuses. A previous study reported that 
infants of Filipino mothers had twice the risk of developing macrosomia than other 
Pacific Islander subgroups in the US.212  
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The mean body mass index (BMI) between different genotypes of UA genes  
Hyperuricemia has been reported to be associated with obesity metabolic traits 
such as dyslipidemia.213 Urate genetic polymorphism could contribute to that 
association. A recent study has found an association between GCKR (rs780094 C>T) 
and multiple types of lipids, which may cause obesity and several other metabolic 
complications.152 We utilized a univariate analysis ANOVA test to assess the 
differences of mean BMI across the UA genes in different genetic models (additive, 
dominant, and recessive). In the Filipino cohort, the analysis showed carriers risk of TT 
genotype had a higher mean BMI relative to CC genotype (reference) of GCKR (780094 
C>T), but these results were not statistically significant. (P>0.05). (Table 3.8).  
Conversely, in the same Filipino cohort, we found a significant difference in mean BMI 
under the dominant model (GG (reference) vs. GT+TT) of ABCG2 (rs2231142 G>T). 
The participant carriers GT+TT had a lower mean BMI of 24.14 relative to GG 
(reference) 26.88. (p=0.04). (Table 3.8). These results were in conflict with the 
published literature, as previous studies have found a loss of function in ABCG2 
(rs2231142 G>T) variant associated with gout in obese male compared to nonobese 
females in a subset of Taiwanese patients.214 On the other hand, in the Samoan 
population cohort, our analysis found a trend toward significant in the mean BMI of 
GCKR (780094 C>T) genotypes. The mean BMI under the additive model CC 
(reference) vs. TT (risk genotype) of GCKR (780094 C>T) was significantly lower in 
the TT genotype, around 26.56 compared to 29.72 in CC (reference) genotype of GCKR 
(p=0.082) (Table 3.9). In addition, in the same Samoan cohort, a significant difference 
of mean BMI and LRRC16A (rs742132 A>G) genotypes were found under additive and 
recessive models. The mean BMI of the AA genotype of the LRRC16A additive model 
was about 27.47 lower compared to the GG genotype of 28.65 (reference) (p=0.033). 
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Also, the mean BMI of the AA genotype of the LRRC16A recessive model was lower, 
around 27.47, compared to AG+GG (reference), about 30.31 (p=0.031). (Table 3.9).  
Numerous risk factors, both genetic and non-genetic, contribute to the increased 
risk of cardiometabolic disorders. From a genetic perspective, women of Asian 
ancestry, mainly Filipino pregnant women, had a higher frequency of HU risk alleles 
that could partially match their risk of developing metabolic disorders. On the other 
hand, apart from non-genetic risk factors, both Samoan and Filipino pregnant women 
show significant non-genetic risk factors, including age and BMI, associated with 
metabolic disorders. 
Limitations 
This study is retrospective, so we were limited to a certain number of genetic 
and nongenetic risk factors. We conducted our investigation between genotypes and 
phenotypes only on limited UA genetic polymorphisms from the genetic side. 
Meanwhile, on the nongenetic side, we only assessed age and BMI as predictors 
associated with developments of CMDs. We believe that other factors associated with 
CMDs are lifestyle, diet, physical activity, smoking, and alcohol use. The average age 
of pregnant women in this study was 28 years old, and at this age, the proportion of 
comorbid disorders is lower than in older age. In addition, the frequency of some UA 
risk alleles in the presence of diseases was very low, which may have affected the exact 
results and the exact association between genetic/nongenetic risk factors and 
cardiometabolic disorders. Finally, the data was convenient, selected from one 
geographical location and one hospital on the same average age. Further studies should 
be conducted on a more representative and larger sample size to validate our results. 
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Conclusion 
         Our analysis found that HU/gout risk alleles and other factors such as age and 
BMI are associated with the development of CMDs in the selected Asian-Pacific 
Islander populations. These study findings are consistent with already published studies 
that explain the biological function of UA gene heritability and other demographic 
factors in CMDs development. Genetically, our results have found both Filipinos and 
Samoans may be at a higher risk of CMDs due to HU risk alleles in ABCG2 (rs2231142 
G>T) and SLC22A11 (rs17300741 A>G). 
 Other factors, including age and BMI, are reported as high-risk factors 
associated with the development of CMDs across both Samoan and Filipino 
populations. We believe that further studies across different populations will support 
our hypothesis. Finally, we would say that the difference in the prevalence of comorbid 
diseases across populations could partially be explained by different genetic 
backgrounds. Hence, this study suggests that the Asian population in the Filipino 
subgroup is at a higher risk of CMDs due to numerous risk factors, including both 




Table 3.1: Demographic Characteristics across Filipino and Samoan populations 
Characteristics Total population 





p-value (Filipino vs 
Samoans) 
Mother’s age (years) 28.8±6.3 29.8±6.1* 26.3±5.7* 1.391e-09 
Gestational age (weeks) 38.0±2.27 37.82±2.27** 38.4±2.0* 0.004 
Preterm (<37 weeks) 182 (17.3%) 44 (19.4%)** 27 (13.5%)** 0.17 
Full term (≥37 weeks) 871 (82.2%) 183 (80.63%)** 173 (86.5%)** 0.58 
Body mass index (kg/m2)  26.3±6.9 25.0±6.0* 30.1±7.5* 
 
4.758e-12 




Table 3.2: Clinical and Social Characteristic among Filipino and Samoan Ethnicities 






p-value (Filipino vs 
Samoans) 
Premature labor 169 (15.9%) 36 (15.7%)** 27 (13.5%)** 0.00001 
Gestational diabetes mellitus 137 (12.9%) 48 (20.9%)* 23 (11.0%)** 0.0255 
Diabetes mellitus 19 (1.8%) 4 (1.7%)** 6 (3.0%)** 0.401 
Gestational hypertension 38 (3.6%) 6 (2.6%)** 9 (4.5%)** 0.307 
Chronic hypertension 50 (4.7%) 21 (9.1%)* 7 (3.5%)** 0.0259 
Mild preeclampsia 41 (3.9%) 10 (4.3%)** 14 (7.0%)** <0.00001 
Severe preeclampsia 15 (1.4) 8 (3.5%)* 4 (2.0%)** 0.1574 
Eclampsia 1 (0.1) 1 (0.4%)** - - 
History of alcohol intake 27 (2.5%) 4 (1.7%)** 4 (2.0%)** 0.01833 
History of smoking 162 (15.3%) 17 (7.4%)* 56 (28.0%)** <0.00001 
*Indicates significant value at p <0.05 of Chi-square analysis relative to the total population 
**Indicate non-significant value at p<0.05 of Chi-square analysis relative to the total population 
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Table 3.3: Clinical and Social Characteristic among Asian and Non-Asian population (NHPIs) 






p-value (Asian vs 
NHPIs) 
Premature labor 169 (15.9%) 95 (17.5%)** 74 (14.3)** 0.2327 
Gestational diabetes mellitus 137 (12.9%) 90 (16.6%)** 47 (9.1%)* 0.0014 
Diabetes mellitus 19 (1.8%) 7 (1.3%)** 11 (2.3%)** 0.2972 
Gestational hypertension 38 (3.6%) 17 (3.1%)** 21 (4.1%)** 0.4282 
Chronic hypertension 50 (4.7%) 36 (6.6%)** 14 (2.7%)** 0.0041 
Mild preeclampsia 41 (3.9%) 20 (3.6%)** 21 (4.1%)** 0.7538 
Severe preeclampsia 15 (1.4) 10 (1.9%)** 5 (0.9%)** 0.2362 
Eclampsia 1 (0.1) 1 (0.18)** 0 - 
History of alcohol intake 27 (2.5%) 14 (2.6%)** 13 (2.5%)** 0.9527 
History of smoking 162 (15.3%) 39 (7.2%)* 23.8%)* 0.0748 
*Indicates significant value at p <0.05  
**Indicate non-significant value at p<0.05  
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 Table 3.4: Association of UA Risk Alleles and CMDs Across the Samoan Subgroup- continue 










































































































































































Table 3.4: Association of UA Risk Alleles and CMDs Across the Samoan Subgroup- continue 







































































































































































Table 3.4: Association of UA Risk Alleles and CMDs Across the Samoan Subgroup- continue 







































































































































































Table 3.4: Association of UA Risk Alleles and CMDs Across the Samoan Subgroup- continue 



































































































Table 3.5: Association of UA Risk Alleles and CMDs Across the Filipino Subgroup 
Gene (SNP) Chronic Hypertension Gestational Hypertension Diabetes Mellitus Gestational diabetes Mellitus 














































































































































































Table 3.5: Association of UA Risk Alleles and CMDs Across the Filipino Subgroup- continue 









































































































































































Table 3.5: The Association of UA Risk Alleles and CMDs Across the Filipino Subgroup- continue  




























































68.4 (115)  
















































































































Table 3.5: Association of UA Risk Alleles and CMDs Across the Filipino Subgroup- continue 




































































































Table 3.6: Hardy Weinberg Equilibrium (HWE) Assessment of 
Targeted SNPs 
Gene/SNP Filipino Samoan 
SLC17A1 (rs1183201) 0.7789 0.3326 
PDZK1(rs12129861) 0.0000** 0.0000** 
SLC22A11(rs17300741) 0.4439 0.4465 
ABCG2 (rs2231142) 0.6376 0.3942 
SLC16A9 (rs2242206) 0.1473 0.0275** 
SLC22A12 (rs505802) 0.8183 0.2042 
SLC2A9 (rs734553) 0.8788 0.8211 
LRRC16A (rs742132) 0.8602 0.4492 
GCKR (rs780094) 0.3981 0.9620 
** Indicates for deviated from HWE p<0.05 
 97 
 
Table 3.7: Association of BMI & Age (non-genetic factors) with Cardiometabolic Diseases (CMDs) in Filipino and Samoan 





















































































R2 7.0% 7.0% 3.0% 7.0% 6.0% 8.0% 6.0% 11.0% 
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Sum Mean SD 95% CI ANOVA-  
p-value 
SLC22A11(rs17300741A>G) (Additive) 
AA  0.247 109 25.34 6.74 24.06-26.62 0.371 
AG 37 24.26 5.97 22.27-26.25 
GG (Ref.) 5 23.06 3.47 18.74-27.37 
SLC22A11 (Dominant) 
GG (Ref.) 0.157 5 25.34 6.74 24.06-26.62 0.496 




0.217 42                   24.11 5.71 21.71-35.13 0.299 
AA 109 25.34 6.74 24.06-26.62 
SLC22A12 (rs505802 C>T) 
CC 0.1704 94 25.16 6.12 22.71-25.85 0.388 
CT 58 25.03 6.91 23.62-26.45 
TT (Ref.) 6 22.95 3.46 22.80-28.72 
SLC22A12 (Dominant) 
TT (Ref.) 0.119 6 25.16 6.12 22.71-25.85 0.413 




0.450 64 24.83 6.67 19.31-26.58 0.754 
CC 94 25.16 6.12 22.71-25.85 
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Table 3.8: Association between Uric Acid Risk Alleles and BMI across the Filipino 




Sum Mean SD 95% CI ANOVA-  
p-value 
ABCG2 (rs2231142 G>T) (Additive) 
GG (Ref.) 0.00243 45 26.88 8.12 24.44-29.32 0.1204 
GT 79 24.17 5.64 22.91-25.44 
TT 31 24.04 4.82 22.27-25.81 
ABCG2 (Dominant) 
GG (Ref.) 0.00075 45 26.88 8.12 24.44-29.32 0.041 




0.030 124 25.16 6.74 19.31-26.58 0.295 
TT 31 24.04 4.82 22.27-25.81 
SLC16A9 (rs2242206 G>T) (Additive) 
GG (Ref.) 0.448 56                    30.18 7.78 23.28-26.87 0.982 
GT 85                   29.47 6.82 23.34-26.47 
TT 16 27.7 8.20 22.63-27.04 
SLC16A9 (Dominant) 
GG (Ref.) 0.403 56                    30.18 7.78 23.28-26.87 0.416 




0.486 141                   29.75 7.20 28.55-30.95 0.287 
TT 16 27.7 8.20 22.63-27.04 
GCKR (rs780094) (Additive) 
CC (Ref.) 0.04043 53 24.28 5.69 22.71-25.85 0.614 
CT 71 25.04 5.98 23.62-26.45 
TT 32 25.76 8.20 22.80-28.72 
GCKR (Dominant) 
CC (Ref.) 0.180 53 24.28 5.69 22.71-25.85 0.365 




0.011 124                                24.71 5.85 23.67-25.75 0.500 
TT 32 25.76 8.20 22.80-28.72 
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SUM Mean SD 95% CI ANOVA-  
p-value 
LRRC16A (rs742132 A>G) (Additive) 
AA 0.04307 78 25.78 7.22 24.15-27.41 0.2523 
AG 62 24.23 5.38 22.86-25.60 
GG (Ref.) 15 23.54 5.43 20.53-26.55 
LRRC16A (Dominant) 
GG (Ref.) 0.393 15 23.54 5.43 20.53-26.55 0.374 




0.0100 77 24.10 5.36 22.88-25.32 0.101 
AA 78 25.78 7.22 24.15-27.41 
SLC17A1 (rs1183201 A>T) (Additive) 
AA (Ref.) 0.003144 6 23.71 3.39 20.15-27.27 0.469 
AT 47 25.95 8.05 23.58-28.31 
TT 98 24.61 5.56 23.50- 25.73 
SLC17A1 (Dominant) 
AA (Ref.) 0.105 6 23.71 3.39 20.15-27.27 0.618 




0.006 53 25.69 7.68 23.57-27.81 0.368 
TT 98 24.61 5.56 23.50- 25.73 
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Sum Mean SD 95% CI ANOVA-  
p-value 
SLC22A11 (rs17300741 A>G) (Additive)  
AA 0.877 97 29.61 7.53 24.06-26.62 0.921 
AG 48 29.42 7.13 22.27-26.25 
GG (Ref.) 8 28.42 8.02 18.74-27.37 
SLC22A11 (Dominant) 
GG (Ref.) 0.759 8 28.42 8.02 18.74-27.37 0.676 
AG+AA 145                   29.55 7.38 28.33-30.76 
SLc22A11 (Recessive) 
AG+GG (Ref.) 0.711 56                   29.28 7.20 28.09-31.12 0.792 
AA 97 29.61 7.53 24.06-26.62 
SLC22A12 (rs505802 C>T) (Additive)  
CC 0.7864 79 28.88 7.38 23.91-26.41 0.471 
CT 61 30.38 7.48 23.21-26.84 
TT (Ref.) 18 30.14 6.52 19.31-26.58 
SLC22A12 (Dominant) 
TT (Ref.) 0.490 18 30.14 6.52 19.31-26.58 0.718 
CT+CC 140 29.53 7.43 28.29-30.78 
SLC22A12 (Recessive) 
CT+TT (Ref.) 0.859 79 30.33 7.23 26.90-33.38 0.214 
CC 79 28.88 7.38 23.91-26.41 
ABCG2 (rs2231142 G>T) (Additive) 
GG (Ref.) 0.1618 75 29.22 7.04 24.44-29.32 0.760 
GT 64 30.11 6.90 22.91-25.44 
TT 17 29.57 9.69 22.27-25.81 
ABCG2 (Dominant) 
GG (Ref.) 0.574 
 
75 29.22 7.04 24.44-29.32 0.508 
GT+TT 81                         30       7.51 28.33- 31.66 
ABCG2 (Recessive) 
GG+GT (Ref.) 0.05 139 29.63 6.97 26.90-33.38 0.981 
TT 17             29.57 9.69 22.27-25.81 
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SUM Mean SD 95% CI ANOVA-  
p-value 
GCKR (rs780094 C>T) (Additive) 
CC (Ref.) 0.171 77 29.72 7.83 22.71-25.85 0.082 
CT 66 30.28 6.92 23.62-26.45 
TT 14 26.56 5.19 22.80-28.72 
GCKR (Dominant) 
CC (Ref.) 0.201 77 29.72 7.83 22.71-25.85 0.936 




0.119 143                   29.98 7.40 28.75-31.20 0.094 
TT 14 26.56 5.19 22.80-28.72 
LRRC16A (rs742132 A>G) (Additive)  
AA 0.414 41 27.47 7.21 24.15-27.41 0.033 
AG 84 30.92 6.73 24.15-27.41 
GG (Ref.) 31 28.65 8.18 22.86-25.60 
LRRC16A (Dominant) 
GG (Ref.) 0.291 31 28.65 8.18 22.86-25.60 0.437 




0.976 115                   30.31  7.18 28.98-31.64 0.031 




Table 3.9:  Association between Uric Acid Risk Alleles and BMI across the 




SUM Mean SD 95% CI ANOVA-  
p-value 
SLC17A1 (rs1183201 A>T) (Additive) 
AA (Ref.) 11 29.79 8.76 20.15-27.27 0.393 
AT 64 30.46 7.49 23.58-28.31 
TT 81 28.75 7.00 23.50-25.73 
SLC17A1 (Dominant) 
AA (Ref.) 11 29.79 8.76 20.15-27.27 0.902 




75 30.36 7.63 28.60-32.12 0.172 




Table 3.10: Abbreviations 
NHPI Native Hawaiian and Pacific Islander population 
CMDs Cardiometabolic diseases 
DM Diabetes Mellitus  
GDM Gestational Diabetes Mellitus 
CHTN Chronic hypertension  
GHTN Gestational hypertension  
SU Serum uric acid  
PE Preeclampsia 
IR Insulin resistance 
NO Nitric oxide 
PKC Phosphokinase-c 
PI3K Phospho inositol-3 kinase 
BMI Body Mass Index 
IUGR Intrauterine growth restriction 






Figure 3.1: The prevalence of comorbid diseases across Asian and native Hawaiian-











The prevalence of GDM and CHTN were significantly higher in Asian versus non-Asian 



















The prevalence of GDM and CHTN were significantly higher in Filipino versus Samoan 





























































































The prevalence of hyperuricemia and gout disease among the US population 
varies due to differences in genetic backgrounds. Many studies conducted on several 
racial groups reported that individuals of those racial groups experience a higher rate of 
hyperuricemia (HU)/gout conditions when compared with Europeans. Participants in 
this study were selected from the Hawaii area and were of diverse races, confirming that 
the prevalence of disease variability was not similar between subgroups. The Asian and 
Pacific Islander groups are two of the largest minorities living in the US; the Filipino 
minority group is the second largest Asian sub-population after the Chinese sub-group, 
and the Samoan sub-group is the largest minority group across Pacific Islanders. 
This study found that the Asian subgroups, including Filipinos, Koreans, and 
Japanese, had the highest UA risk alleles relative to other minorities. Moreover, they 
also had a high prevalence of comorbidities, such as hypertension and diabetes mellitus. 
Our cross-sectional study was retrospective, and we were limited to specific uric acid 
(UA) gene/SNPs pairs associated with the development of HU/gout. That limitation 
provides potential direction in terms of further research opportunities across several UA 
genes. After analyzing our preliminary findings, we can partially confirm that the Asian 
population living in the US is at higher risk of rheumatological diseases, particularly 
HU/gout. 
Genetic investigations among different populations could assess and aid 
knowledge as to why some diseases present higher in some ethnicities when compared 
to others. These differences detected might provide insights to allow clinicians and 
clinical researchers to think about the best ways of diagnosing and treating patients. 
Hence, our results may improve patient and health care outcomes by investigating 
diseases and selecting the proper drug at the proper dose for individual patients. Also, 
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genetic testing could enhance both the health care system and patients’ treatment 
options through decreased healthcare costs associated with incorrect prescribing.  
Physiologically, the UA transportome genes show a role in metabolic diseases 
through specific pathological mechanisms. These mechanisms might explain the 
relationship between UA genes loss of function or polymorphism, and why they can 
result in some disorders like insulin resistance or elevated blood pressure. Mendelian 
randomization, for example, suggests that not all patients who have a high UA level 
would have gout disease, though a high percentage of them might develop 
cardiometabolic-related complications. UA risk alleles should be considered a 
predictive diagnostic parameter in metabolic diseases together with other risk factors. 
Consistent with the epidemiology of gout, women of child-bearing age are 
unlikely to develop gout, despite their having the genetic risk factors for HU/gout. The 
presence of hormones like estrogen plays an essential role in UA excretion in females, 
particularly premenopausal women. Estrogen is a nuclear hormone and has a role in 
urate efflux through the increased expression of the ABCG2 gene, which is responsible 
for urate excretion. Additionally, the estrogen hormone suppresses the URAT1 genes 
like SLC22A12, causing changes in urate reabsorption activity. Therefore, further 
studies involving women and men of different ages are needed to compare UA levels 
more accurately. 
In summary, this study’s findings add clarity to the prevalence of UA risk alleles 
among the different populations. The difference in the genetic background across 
populations could explain a part of HU/gout risk factors and why a prevalence of these 
conditions vary among different ethnicities. Several investigational studies are essential 
to validate these results.  
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Genetic polymorphisms, particularly UA risk alleles, have a role in the 
development of cardiometabolic syndromes. In the final chapter, we reported on genetic 
polymorphisms associated with developing different metabolic disorders like diabetes 
mellitus, gestational diabetes mellitus, and chronic hypertension. The forementioned 
comorbidities are considered significant risk factors for the maternal preeclampsia (PE), 
affecting both the mother and fetus. The pathophysiology of PE could partially happen 
indirectly through metabolic syndromes, and there is a role played by the UA 
transporter in the progression of metabolic traits. That, in turn, leads to an investigation 
of the association between UA risk alleles and the development of cardiometabolic 
diseases (CMDs). Several studies have reported the prevalence of PE in some ethnic 
groups such as African Americans. On the other hand, limited studies have reported risk 
factors or causes of PE on different ethnicities. Our study findings add feasibility and 
clarify information on the diverse populations that have a high risk of developing PE. 
These results assess and provide more knowledge on health inequalities between 
different racial groups.  
The risk of PE has been reported to have increased up to six-fold between 1980 
and 2003 in the US population. Specifically, the Asian-Pacific Islander population 
living in Hawaii has a higher prevalence of PE. Filipino and Samoan American 
subgroups have the highest prevalence of comorbidities like gestational diabetes 
mellitus, which ultimately leads to an increased risk of PE by around 30%. Moreover, 
PE disease increases the risk of maternal and fetus defects, significantly increasing the 
associated cost of health care by about $2.18 billion. 
These results have shown that Filipinos living in Hawaii are at a higher risk of 
developing metabolic diseases, particularly diabetes mellitus, due to UA genetic 
polymorphisms as compared to the Samoan subgroup. This study finding is to be 
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partially consistent with other studies that reported that Filipino American women in the 
US had the highest incidence of PE when compared to Chinese and Samoan Pacific 
Islander women. More studies investigating the relationship between UA genetic defect 
and prevalence of metabolic disorders will help validate and generalize our results, 
contributing to personalized medicine in diagnostic and treatment disease approaches. 
From a non-genetic perspective, there are many risk factors associated with the 
development of PE. Examples of these factors include younger/advanced age and body 
mass index above the normal range. Our findings have shown that the Asian/Pacific 
Islander population is at a higher risk of cardiometabolic disorders, and that could be 
partially due to age and BMI, in addition to other risk factors. Besides these risk factors, 
we believe that other factors associated with PE development include lifestyle, 
socioeconomic status, and psychological disorders. 
          These preliminary findings have shown both genetic and non-genetic risk factors 
associated with developing cardiometabolic disorders. The Asian population, for 
instance, had significantly higher UA risk alleles and cardiometabolic diseases relative 
to the native Hawaiian and Pacific Islander populations. Furthermore, the Filipino sub-
Asian population had the highest prevalence of both UA risk alleles and 
cardiometabolic syndromes such as gestational diabetes and chronic hypertension as 
compared to the Samoan population. Future prospective cross-sectional studies should 
be conducted on different ages and ethnicities, and large representative sample sizes 
should be included to validate our results findings.  
Future prospective 
        The risk factors contributing to HU/gout diseases vary across different ethnicities 
and between males and females. Investigational tools, particularly from a genetic 
perspective, greatly help detect possible genetic differences between minorities. This 
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study was retrospectively conducted on only pregnant women. A prospective 
investigational study on different racial and age groups is necessary to more fully 
develop our findings. Moreover, the current study was limited to specific UA 
gene/SNPs from Genome-Wide Association Studies performed on EUR ancestry. 
Additionally, the sample size was drawn from a limited location with a younger age 
average.  
        We believe that these findings could achieve in the creation of personalized 
treatment options under individual genetic profiles. Detecting genetic polymorphisms 
that have physiological and pathological roles in diseases could minimize the health 
disparities between minorities. Conducting community-based research will help engage 
different populations at higher risks of certain diseases, particularly gout. To our 
knowledge, this research project is the first study performed on pregnant women from 
different genetic backgrounds. This study is also the first study that reported the genetic 
association between UA risk alleles and cardiometabolic complications in pregnant 
women across different races. These findings could expand the clinical research 
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        In this section, we would mention how we got these results after doing different 
statistical analyses. First, we tried to build the logistic regression model to detect an 
association between phenotypes and UA risk alleles in the different genetic models, 
adjusting for other covariates, including age and body mass index across the whole 
sample size. In this test findings, we did not get an exact result because if we aggregated 
the population into one group, we assume that the variability around whatever covariate, 
such as SNPs or genotype, is similar across all subgroups. Nevertheless, this is not true 
because the variability is different around the UA-genotype. Furthermore, we reported 
that in the appendix (Section 6.A) as an example.  
        Then we decided to focus our hypothesis test on the Filipino population as one 
group of Asian minorities and Samoan population as one group of Pacific Islander 
population. Our selection depended on the several factors involved in those ethnicities 
known as major minorities in the US. It is also they have the largest sample size of 
participants amongst other populations in the data. In addition, they reported the highest 
prevalence of both metabolic and maternal conditions in our dataset. (Table 3.2). We 
started to test our hypothesis that aimed to detect an association between 
cardiometabolic diseases (CMDs) and both genetic (uric acid (UA) risk alleles) and 
non-genetic (age/BMI) using logistic regression analysis. In the first step, we conduct a 
simple logistic model to detect an association between metabolic diseases and BMI 
covariate, then we add to the model age/BMI. In this analysis, we decided to select both 
age/BMI as covariates associated with phenotypes (Section 6.B). The selection was 
based on the global hypothesis test and R2 results, which explain how close the data are 
to the fitted regression in both models. (Table 3.7).  
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         Then we were built a model adding other covariates involve UA genotypes 
besides age/BMI using multiple logistic regression analysis. Unfortunately, the results 
were uninterpretable because they were biologically and directionally inconsistent with 
some UA genes toward cardiometabolic diseases (Section 6.C). We assumed that might 
partly be due to the low frequency of the outcomes. Although the multiple logistic 
regression results were uninterpretable with some genes, it gave us a signal about non-
genetic risk factors associated with CMDs developments. These findings led us to think 
about doing other statistical analyses to figure out the association between 
cardiometabolic phenotypes and UA genotypes.  
          We moved to use chi-square or Fisher exact test as appropriate. We found an 
interesting significant result in several UA genes that are biologically associated with 
cardiometabolic diseases developments across both Filipino and Samoan populations. It 
should be noted that these results consistent with the previous study that we found 
Asians overall and Filipino, in particular, had the highest prevalence of UA risk alleles 
compared to Pacific Islanders population. (Table 2.5) Moreover, in characteristic 
clinical information, our results have shown Asian population had a significantly higher 
metabolic diseases relative to Native Hawaiian and Pacific Islanders. The same analysis 
has found Filipino population had a significant prevalence of metabolic diseases. 
In the final analysis, we conducted univariate (ANOVA) to assess the mean of BMI 
across the different UA genes. First, we selected equal or unequal ANOVA depend on 
the Bartlett’s test results, which assess the homogeneity of variance (Table 3.8 & Table 
3.9). We found mean BMI in some genes consistent with biology and literature amongst 
the Filipino subgroup, but there was insufficient evidence to support that association. 
On the other hand, we found a significantly lower mean of BMI in some UA genes in 
both Filipino and Samoan. 
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          Overall, this study discussed both genetic and genetic risk factors associated with 
metabolic syndromes in Filipino and Samoan populations using different statistical 
analyses. These findings were found Asian overall, and Filipino subgroup in particular 
at high risk of metabolic syndromes due to both UA risk alleles and age/BMI compares 
to Pacific Islanders population generally and Samoan.  
Section 6.A:  The logistic regression analysis results across the whole population 
Table1. Association between chronic hypertension and UA risk alleles across the 
whole population sample (Simple Logistic regression)  
Gene/SNP Test model Odds 
Ratio 

















































































0.99 0.613-1.655 0.984 

















Table 1.A.  CHTN vs. dominant models of UA genotypes + BMI+ age across the 
whole population  
Measurements OR 95% CI p-value 
 BMI 1.07 1.027-1.118 0.000984 *** 
Mother age 1.13 1.070-1.213 5.37e-05 *** 
SLC17A1 (rs1183201 
T>A) 
1.48 0.382-10.106 0.619781 
GCKR (rs780094 
C>T) 




0.48 0.165-1.769 0.215692 
SLC16A9 (rs2242206 
G>T) 
0.80 0.382-1.787 0.578133 
LRRC16A (rs742132 
G>A) 









Table 1.B.  CHTN vs. recessive models of UA genotypes + BMI+ age across the 
whole population 
Measurements OR 95% CI p-value 
 BMI 1.07 1.028-1.120 0.000893 *** 
Mother age 1.15 1.081-1.229 1.74e-05 *** 
SLC17A1 (rs1183201 
T>A) 
0.38 0.166-0.865 0.023208 * 
GCKR (rs780094 
C>T) 
1.74 0.726-3.880 0.189174 
SLC22A12 (rs505802 
C>T) 
0.63 0.302-1.320 0.220837 
SLC16A9 (rs2242206 
G>T) 

















Table2. Association between GHTN and UA risk alleles across the whole 
population (Logistic regression) 





































































0.90 0.421- 2.106 0.805 
Recessive 






























Table 2.A.  GHTN vs. dominant models of UA genotypes +BMI+ mother age 
across the whole population 
Measurements OR 95% CI p-value 
 BMI 1.07 1.025-1.121 0.001431 ** 
Mother age 1.03 0.968-1.105 0.307908 
SLC17A1 (rs1183201 
T>A) 
2.82 0.530-52.824 0.329488 
GCKR (rs780094 
C>T) 
1.36 0.576-3.498 0.497834 
SLC22A12 (rs505802 
C>T) 
0.49 0.152-2.205 0.280605 
SLC16A9 (rs2242206 
G>T) 
0.70 0.307-1.700 0.411459 
LRRC16A (rs742132 
G>A) 











Table 2.B.  GHTN vs. recessive models of UA genotype +BMI+ mother age across 
the whole population 
Measurements OR 95% CI p-value 
 BMI 1.07 1.025-1.121 0.00151 ** 
Mother age 1.03 0.965-1.103 0.35517 
SLC17A1 (rs1183201 
T>A) 
1.89 0.780-4.924 0.16884 
GCKR (rs780094 C>T) 0.85 0.240-2.381 0.78913 
SLC22A12 (rs505802 
C>T) 
0.92 0.411-2.150 0.85971 
SLC16A9 (rs2242206 
G>T) 
0.89 0.291-2.292 0.83196   
LRRC16A (rs742132 
G>A) 





Table3. Association between DM and UA risk alleles across the whole population 
sample (Logistic regression) 
Gene/SNP Test model Odds 
Ratio 





























































































































Table 3.A.  DM vs. dominant models of UA genotypes +BMI+ mother age across 
the whole population 
 144 
Measurements OR 95% CI p-value 
 BMI 1.07 1.000-1.151 0.035402 * 
Mother age 1.21 1.099-1.367 0.000362 *** 
SLC17A1 (rs1183201 
T>A) 
0.18 4.334797e-02-0.911 0.025620 * 
GCKR (rs780094 
C>T) 
0.47 0.142-1.533 0.208353 
SLC22A12 (rs505802 
C>T) 
0.24 6.489311e-02-1.137 0.050988 
SLC16A9 (rs2242206 
G>T) 
0.91 0.279-3.551 0.887322 
LRRC16A (rs742132 
G>A) 





Table 3.B.  DM vs. recessive models of UA genotypes+ BMI+ mother age across the 
whole population sample 
Measurements OR 95% CI p-value 
 BMI 1.07 0.998- 1.148 0.041939 * 
Mother age 1.21 1.105-1.360 0.000162 *** 
SLC17A1 (rs1183201 
T>A) 
0.20 4.008983e-02-0.749 0.027274 * 
GCKR (rs780094 
C>T) 
0.79 0.118-3.190 0.773659 
SLC22A12 (rs505802 
C>T) 
1.54 0.497-5.422 0.463180 
SLC16A9 (rs2242206 
G>T) 
0.29 0.155-1.585 0.247074 
LRRC16A (rs742132 
G>A) 






Table4. Association between GDM and UA risk alleles across the whole population 
sample (Logistic regression) 
Gene/SNP Test model Odds 
Ratio 

































































































Table 4.A.  GDM vs. dominant models of UA genotype + BMI+ age across the 
whole population 
Measurements OR 95% CI p-value 
 BMI 1.04 1.011-1.070 0.00588 ** 
Mother age 1.10 1.064-1.144 9.12e-08 *** 
SLC17A1 (rs1183201 
T>A) 
1.20 0.526-3.271 0.68266 
GCKR (rs780094 C>T) 0.75 0.481-1.185 0.21606   
SLC22A12 (rs505802 
C>T) 
2.00 0.756-6.957 0.20840 
SLC16A9 (rs2242206 
G>T) 
0.62 0.395-0.982 0.03914 * 
LRRC16A (rs742132 
G>A) 









Table 4.B.  GDM vs. Recessive models of UA genotype + BMI+ age across the 
whole population 
 147 
Measurements OR 95% CI p-value 
 BMI 1.03 1.008-1.068 0.00894 ** 
Mother age 1.10 1.062-1.142 2.02e-07 *** 
SLC17A1 (rs1183201 
T>A) 
1.35 0.842-2.189 0.21441 
GCKR (rs780094 C>T) 0.69 0.373-1.219 0.22306 
SLC22A12 (rs505802 
C>T) 
1.04 0.675-1.633 0.84342 
SLC16A9 (rs2242206 
G>T) 
1.16 0.692-1.906 0.55293 
LRRC16A (rs742132 
G>A) 









Section 6.B: The simple model between phenotype versus BM and phenotype versus 
both age/BMI  
 
Association of BMI + Age (non-genetic factors) with Cardiometabolic diseases 
(CMD) in Filipino and Samoan (Simple model) 
 
A. Filipino subgroup 
 























Filipino, CHTN, (Global test) 
CHTN vs. BMI  
Adjusted R-square Global statistic  DF P-value  
0.0214 2.797 1 0.094 
 Filipino, CHTN, (second hypothesis test) 
BMI OR SE 95% CI p-value 
1.05 0.032 0.98- 1.12 0.081 
Filipino, CHTN, (Global test) 
CHTN vs. BMI + mother age  
Adjusted R-square Global statistic DF P-value  
0.07 9.602 2 0.008 
 Filipino, CHTN, (second hypothesis test) 
 OR SE 95% CI p-value 
BMI 1.06 0.033 0.99- 1.13 0.06 



































Filipino, GHTN, (Global test) 
GHTN vs. BMI  
Adjusted R-square Global test  DF P-value  
0.0334 1.311 1 0.252 
 Filipino, GHTN, (second hypothesis test) 
BMI OR SE 95% CI p-value 
1.07 0.055 0.93- 1.18 0.193 
Filipino, GHTN, (Global test) 
GHTN vs. BMI + mother age  
Adjusted R-square Global test  DF  P-value  
0.034 1.34 2 0.511 
GHTN, (second hypothesis test) 
 OR SE 95% CI p-value 
BMI 1.07 0.056 0.93-1.19 0.193 



































Filipino, DM, (Global test) 
DM vs. BMI  
Adjusted R-square Global test  DF P-value  
0.0008 1.34 1 0.246 
 Filipino, DM, (second hypothesis test) 
BMI OR SE 95% CI p-value 
 0.98 0.103 0.76- 1.14 0.877 
Filipino, DM, (Global test) 
DM vs. BMI + mother age  
Adjusted R-square Global Test  DF P-value  
0.067 2.09 2 0.351 
Filipino, DM, (second hypothesis test) 
 OR SE 95% CI p-value 
BMI 0.98 0.101 0.77- 1.16 0.880 



































Filipino, GDM, (Global test) 
GDM vs. BMI only 
Adjusted R-square Global test  DF P-value  
0.0017 0.381 1 0.536 
 Filipino, GDM, (second hypothesis test) 
BMI OR SE 95% CI p-value 
1.01 0.026 0.96- 1.07 0.532 
Filipino, GDM, (Global test) 
GDM vs. BMI + mother age  
Adjusted R-square Global test  DF P-value  
0.86 14.25 2 8.03e-04 
 Filipino, GDM, (second hypothesis test) 
 OR SE 95% CI p-value 
BMI 1.01 0.027 0.96- 1.07 0.512 




B. Samoan sub-group  
 





























CHTN, (Global test) 
CHTN vs. BMI only 
Adjusted R-square Global statistic  DF P-value  
0.055 3.243 1 0.071 
 Samoan, CHTN, (second hypothesis test) 
BMI OR SE 95% CI p-value 
1.09 0.051 0.99- 1.21 0.075 
Samoan, CHTN, (Global test) 
CHTN vs. BMI + mother age  
Adjusted R-square Global statistic DF P-value  
0.07 4.25 2 0.119 
 Samoan, CHTN, (second hypothesis test) 
 OR SE 95% CI p-value 
BMI 1.08 0.051 0.98-1.20 0.103 



































Samoan, GHTN, (Global test) 
 GHTN vs. BMI only 
Adjusted R-square Global statistic  DF P-value  
0.0598 4.241 1 0.039 
 Samoan, GHTN, (second hypothesis test) 
BMI OR SE 95% CI p-value 
1.09 0.045 1.004- 1.205 0.042 * 
Samoan, GHTN, (Global test) 
GHTN vs. BMI + mother age  
Adjusted R-square Global statistic DF P-value  
0.073 5.242 2 0.072 
 Samoan, GHTN, (second hypothesis test) 
 OR SE 95% CI p-value 
BMI 1.10 0.048 1.01- 1.22 0.031 * 



































Samoan, DM, (Global test) 
DM vs. BMI only 
Adjusted R-square Global statistic  DF P-value  
0.026 1.39 1 0.237 
Samoan, DM, (second hypothesis test) 
BMI OR SE 95% CI p-value 
1.06 0.053 0.95- 1.18 0.236 
Samoan, DM, (Global test) 
DM vs. BMI + mother age  
Adjusted R-square Global statistic DF P-value  
0.086 4.49 2 0.105 
Samoan, DM, (second hypothesis test) 
 OR SE 95% CI p-value 
BMI 1.05 0.054 0.94- 1.17 0.328 












Samoan, GDM, (Global test) 
GDM vs. BMI only 
Adjusted R-square Global statistic  DF P-value  
0.014 1.71 1 0.189 
Samoan, GDM, (second hypothesis test) 
BMI OR SE 95% CI p-value 
1.04 0.031 0.97- 1.11 0.189 
Samoan, GDM, (Global test) 
GDM vs. BMI + mother age  
Adjusted R-square Global statistic DF P-value  
0.116 13.92 2 9.48e-04 
Samoan, GDM, (second hypothesis test) 
 OR SE 95% CI p-value 
BMI 1.03 0.033 0.96- 1.10 0.380 
Age 1.15 0.041 1.06- 1.25 0.0006 *** 
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Table 1.A.1 Shows the secondary hypothesis results of multiple logistic 
regression of CHTN vs. BMI+ mother age+ Additive model of UA genes 
across the Filipino population 
Measurements OR 95% CI p-value 
 BMI 1.03 0.92-1.14 0.490 
Mother age 1.14 1.01-1.31 0.047* 
SLC17A1 (rs1183201 
T>A) 
0.87  0.24-3.88 0.848 
GCKR (rs780094 
C>T) 
0.94 0.35-2.48 0.913 
SLC22A12 (rs505802 
C>T) 
1.31 0.39-6.75 0.713 
SLC16A9 (rs2242206 
G>T) 
0.33 0.08-0.99 0.070 
LRRC16A (rs742132 
G>A) 
1.21 0.40-4.30 0.741 
SLC22A11(rs17300741 2.05 0.50-15.04 0.385 
ABCG2(rs2231142 
G>T) 









Table1. A. Shows the global hypothesis test results of multiple logistic 
regression (additive model) of chronic hypertension (CHTN) vs. BMI + 
Mother’s age + uric acid (UA) genes across the Filipino population  
Adjusted R-square Test statistic DF p-
value 

















Table 1.B.1.  Shows the secondary hypothesis results of multiple logistic 
regression of CHTN vs. BMI+ mother age+ Dominant models of UA genes 
across the Filipino population 
Measurements OR 95% CI p-value 
 BMI 1.03 0.93- 1.13 0.489 
Mother age 1.15 1.02- 1.32 0.032 * 
SLC17A1 (rs1183201 
T>A) 
1.06e+07 2.86e-90-NA 0.995 
GCKR (rs780094 
C>T) 
7.84e-01 018- 4.08 0.751 
SLC22A12 (rs505802 
C>T) 
7.10e+06 5.81e-81-NA 0.995 
SLC16A9 (rs2242206 
G>T) 

















Table 1.C. Shows the global hypothesis test results of multiple logistic 
regression of CHTN vs. BMI + Mother’s age + UA genes across the 
Filipino population 
Adjusted R-square Test statistic DF p-
value 
0.19 12.36 9 0.193 
 
 
Table 1.C.1 Shows the secondary hypothesis results of multiple logistic 
regression of CHTN vs. BMI+ mother age+ Recessive models of UA genes 
across the Filipino population 
Table 1.B. Shows the global hypothesis test results of multiple logistic 
regression (dominant model) of CHTN vs. BMI + Mother’s age + UA genes 
across the Filipino population 
Adjusted R-square Test statistic DF p-value 
0.16 12.23 9 0.200 
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Measurements OR 95% CI p-value 
 BMI 1.06 0.95- 1.16 0.233 
Mother age 1.15 1.01- 1.36 0.049* 
SLC17A1 (rs1183201 
T>A) 
0.68 0.14- 3.59 0.641 
GCKR (rs780094 
C>T) 
2.06 0.25- 1.32 0.449 
SLC22A12 (rs505802 
C>T) 
1.58 0.35- 8.60 0.562 
SLC16A9 (rs2242206 
G>T) 
2.90e-08 NA - 7.40e+49 0.99 
LRRC16A (rs742132 
G>A) 
1.21 0.24- 6.33 0.810 
SLC22A11(rs17300741 
A>G) 
2.30 0.43-18. 82 0.367 
ABCG2(rs2231142 
G>T) 
1.12 0.14- 6.18 0.896 
 
Table 2.A. Shows the global hypothesis test results of multiple logistic 
regression of diabetes mellitus (DM) vs. BMI + Mother’s age + UA genes 
across the Filipino population 
Adjusted R-square Test statistic DF p-value 




Table 2.A.1 Shows the secondary hypothesis results of DM vs. BMI+ mother 
age+ Additive models of UA genes across the Filipino population 
Measurements OR 95% CI p-value 
 BMI 0.99 0.78- 1.21 0.970 
Mother age 1.16 0.92-1.64 0.260 
SLC17A1 
(rs1183201 T>A) 
0.74 8.51e-02 - 7.51 0.778 
GCKR (rs780094 
C>T) 
1.04 0.19- 5.57 0.958 
SLC22A12 
(rs505802 C>T) 
0.48 5.74e-02 - 4.40 0.482 
SLC16A9 
(rs2242206 G>T) 
0.56 6.05e-02 - 3.98 0.574 
LRRC16A 
(rs742132 G>A) 
0.37 4.35e-02 - 2.38 0.306 
SLC22A11 
(17300741 A>G) 
1.00 0.10 - 27.68 0.995 
ABCG2(rs2231142 
G>T) 
2.39 0.38 - 20.50 0.362 
 
 
Table 2.B. Shows the global hypothesis test results of multiple logistic regression 
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of DM vs. BMI + Mother’s age + UA genes across Filipino population 
Adjusted R-square Test statistic DF p-value 
0.36 10.59 9 0.304 
 
Table 2.B.1 Shows the secondary hypothesis results of logistic regression of DM vs. 
BMI+ mother age+ Dominant models of UA genes across the Filipino population 
Measurements OR 95% CI p-value 
 BMI 0.97 0.74 - 1.21 0.858 
Mother age 1.32 1.01- 2.06 0.091 
SLC17A1 
(rs1183201 T>A) 
1.154e+08 5.24e-192 – NA  0.996 
GCKR (rs780094 
C>T) 
2.00 0.10 - 78.61 0.659 
SLC22A12 
(rs505802 C>T) 
3.98e-03 1.46e-06 - 0.34 0.038 * 
SLC16A9 
(rs2242206 G>T) 
0.67 4.11e-02 - 17.83 0.775 
LRRC16A 
(rs742132 G>A) 
9.95e-03 1.72e-06 - 0.86 0.097 
SLC22A11 
(17300741 A>G) 
4.51e+06 3.13e-234 – NA  0.997 
ABCG2(rs2231142 
G>T) 









Table 2.C. Shows the global hypothesis test results of multiple logistic regression of 
DM vs. BMI + Mother’s age + UA genes across the Filipino population  
Adjusted R-square Test statistic DF p-value 




Table 2.C.1 Shows the secondary hypothesis results of DM vs. BMI+ 
mother age+ Recessive models of UA genes across the Filipino population 
Measurements OR 95% CI p-value 
 BMI 0.90 0.71- 1.18 0.708 
Mother age 1.15 0.91- 1.61 0.279 
SLC17A1 (rs1183201 
T>A) 
0.23 8.14e-03 - 3.47 0.303 
GCKR (rs780094 
C>T) 
1.63 6.53e-02 – 24.40 0.717 





7.92e-08 NA - 1.08e+160 0.995 
LRRC16A (rs742132 
G>A) 
0.57 2.27e-02 - 7.83 0.685 
SLC22A11(17300741 
A>G) 
0.62 3.56e-02 – 15.79 0.731 
ABCG2(rs2231142 
G>T) 
6.97 0.581 - 1.73e+02 0.139 
 
 
Table 3.A. Shows the global hypothesis test results of multiple logistic 
regression of gestational hypertension (GHTN) vs. BMI + Mother’s age + 
UA genes across Filipino population 
Adjusted R-square Test statistic DF p-
value 











Table 3.A.1 Shows the secondary hypothesis results of GHTN vs. BMI+ 
mother age+ Additive models of UA genes across Filipino population 
Measurements OR 95% CI p-value 
 BMI 0.69 0.21 - 1.60 0.518 
Mother age 013 1.55e-03 – 0.52 0.358 
SLC17A1 
(rs1183201 T>A) 
7.59e+13 0.00 - NA 0.998 
GCKR (rs780094 
C>T) 










1.73e-02 1.03e-05 - 1.34 0.261 
LRRC16A 
(rs742132 G>A) 
5.52e+20 0.0000 – NA  0.996 
SLC22A11 
(17300741 A>G) 
2.82e+12 0.0000 - NA 0.998 
ABCG2(rs2231142 
G>T) 









Table 3.B. Shows the global hypothesis test results of multiple logistic 
regression of GHTN vs. BMI + Mother’s age + UA genes across the Filipino 
population  
Adjusted R-square Test statistic DF p-value 




Table 3.B.1 Shows the secondary hypothesis results of GHTN vs. BMI+ 
mother age+ Dominant model of UA genes across Filipino population 
Measurements OR 95% CI p-value 
 BMI 1.23 0.97 - 1.686 0.098 
Mother age 0.82 0.54 - 1.142 0.264 
SLC17A1 (rs1183201 
T>A) 
4.65e+06 0.0000 – NA  0.999 
GCKR (rs780094 
C>T) 
0.28 0.007 - 9.126 0.425 
SLC22A12 (rs505802 
C>T) 
1.96e+07 0.0000 - NA 0.999 
SLC16A9 (rs2242206 
G>T) 
0.37 0.009 - 19.681  0.573 
LRRC16A (rs742132 
G>A) 
4.22e+07 0.000 - NA 0.998 
SLC22A11(17300741 
A>G) 
1.26e+08 0.000 - NA 0.999 
ABCG2(rs2231142 
G>T) 





Table 3.C. Shows the global hypothesis test results of multiple logistic 
regression of GHTN vs. BMI + Mother’s age + UA genes across the 
Filipino population  
Adjusted R-square Test statistic DF p-
value 






Table 3.C.1 Shows the secondary hypothesis results of multiple logistic 
regression of GHTN vs. BMI+ mother age+ Recessive model of UA genes 
across the Filipino population 
Measurements OR 95% CI p-value 
 BMI 1.09 0.52-2.16 0.760 
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Mother age 0.57 7.85e-02 - 1.10 0.326 
SLC17A1 (rs1183201 
T>A) 
9.68e+08 0.0000 – NA  0.998 
GCKR (rs780094 
C>T) 
3.05e-06 NA - INF 0.999 
SLC22A12 (rs505802 
C>T) 
3.37e-02 8.782e- 07 - 6.06 0.356 
SLC16A9 (rs2242206 
G>T) 
2.38e-10 NA – INF 0.999 
LRRC16A (rs742132 
G>A) 
3.29e+10 0.000 – NA  0.998 
SLC22A11(17300741 
A>G) 
2.54e+11 0.000 – NA 0.998 
ABCG2(rs2231142 
G>T) 




Table 4.A. Shows the global hypothesis test results of multiple logistic 
regression of gestational diabetes (GDM) vs. BMI + Mother’s age + UA 
genes additive model across the Filipino population  
Adjusted R-square Test statistic DF p-value 
0.06 9.72 9.0 0.37 
 
 
Table 4.A.1 Shows the secondary hypothesis results of multiple logistic 
regression of GDM vs. BMI+ mother age+ dominant models of UA genes 
across the Filipino population 
Measurements OR 95% CI p-value 
 BMI 1.00 -0.05-0.07 0.799 
Mother age 1.09 .027-0.16 0.007 
SLC17A1 
(rs1183201 T>A) 
1.11 -0.67-0.95 0.787 
GCKR 
 (rs780094 C>T) 
0.71 -0.91-0.23 0.254 
SLC22A12 
(rs505802 C>T) 
0.98 -0.73-0.75 0.978 
SLC16A9 
(rs2242206 G>T) 
0.82 -0.76-0.38 0.521 
LRRC16A 
(rs742132 G>A) 
1.02 -0.63-0.70 0.936 
ABCG2(rs2231142 
G>T) 









Table 4.B. Shows the global hypothesis test results of multiple logistic 
regression of GDM vs. BMI + Mother’s age + UA genes in dominant 
model across the Filipino population  
Adjusted R-square Test statistic DF p-
value 




Table 4.B.1 Shows the secondary hypothesis results of multiple logistic 
regression of GDM vs. BMI+ mother age+ dominant model of UA genes 
across the Filipino population  
Measurements OR 95% CI p-value 
 BMI 9.9-01 -0.07-0.05 0.985  
Mother age 1.09 0.02-0.16 0.009 
SLC17A1 
(rs1183201 T>A) 
1.70+07 -147.13-NA 0.992 
GCKR (rs780094 
C>T) 
8.67-01 -1.03-0.78 0.758 
SLC22A12 
(rs505802 C>T) 
1.52+07 -161.88-NA 0.992 
SLC16A9 
(rs2242206 G>T) 
5.49-01 -1.44-0.26 0.168 
LRRC16A 
(rs742132 G>A) 
1.47 -1.10-2.34 0.643 
ABCG2(rs2231142 
G>T) 
7.77-01 -160-0.68 0.589 
SLC22A11 
(17300741 A>G) 









Table 4.C. Shows the global hypothesis test results of multiple logistic 
regression of GDM vs. BMI + Mother’s age + uric acid genes across 
Filipino population (recessive) 
Adjusted R-square Test statistic DF p-
value 
0.08 12.7 9.0 0.173 
 
 
Table 4.C.1 Shows the secondary hypothesis results of GDM vs. BMI+ 
mother age+ Recessive models of UA genes across the Filipino population 
Measurements OR 95% CI p-value 
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 BMI 1.01 -0.05-0.07 0.699 
Mother age 1.10 0.03-0.17 0.004 
SLC17A1 
(rs1183201 T>A) 
1.00 -0.91-0.96 0.994 
GCKR (rs780094 
C>T) 
0.31 -2.46—0.08 0.051 
SLC22A12 
(rs505802 C>T) 
0.97 -0.86-0.84 0.957 
SLC16A9 
(rs2242206 G>T) 
1.42 -0.65-1.30 0.478 
LRRC16A 
(rs742132 G>A) 
0.91 -0.96-0.80 0.851 
ABCG2(rs2231142 
G>T) 




0.90 -0.98-0.83 0.829 
 
 
 
 
 
 
